CURRICULUM VITAE EUROPEAN FORMAT

PERSONAL DATA

Name	Giuseppe Penno
Adress	Via Garcia Lorca 4/I – San Giuliano Terme – 56017 – Pisa
Telephon number	**+39-050-995137; +39-050-995103**
Fax	**+39-050-541521**
Mobile	**+39-347-8865557**
Fiscal Code	**PNN GPP 56D25 G687R**
E-mail	**pgiuse@immr.med.unipi.it**
	giuseppe.penno@unipi.it
Nationality	Italian
Date of birth	April 25, 1956
Place of birth	Piombino (Livorno), Italy

PROFESSIONAL EXPERIENCE

• Date (from - to)	1991-2015 - "Dirigente Ospedaliero di I° Livello" – Azienda Ospedaliero Universitaria di Pisa, Pisa, Italy 2015-present – Associate Professor of Endocrinology and Metabolic Diseases, School of Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

QUALIFICATION

• Date	1983: M.D. degree, cum laude, University of Pisa 1988: Post-Graduate in Internal Medicine, cum laude, University of Pisa 1993: Post-Graduate in Endocrinology and Metabolism, cum laude, University of Pisa

RESERACH EXPERIENCES

Epidemiology of micro- and macrovascular complications in type 1 and type 2 diabetes mellitus (Italian Microalbuminuria Study Group, IMSG; EURODIAB IDDM Complications Study; EURODIAB Prospective Complications Study, EURODIAB PCS; EURODIAB Family Study; Renal Insufficiency And Cardiovascular Events, RIACE Study)

Diabetes, hypertension and diabetic complications: international trials with ACE-inhibitors, Angiotensin II receptor antagonists, renin inhibitors, sulodexide (EUCLID Study; IDNT Study; ALTITUDE; Sulodexide Microalbuminuria Trial, Sun-MICRO; Sulodexide Overt Nephropathy Trial, Sun-MACRO)

Metabolic Syndrome: endothelial dysfunction, impaired glucose tolerance, hypertension

Microalbuminuria and diabetic nephropathy: methods for screening and diagnosis

Genes and microvascular/cardiovascular diabetic complications

Essential hypertension: endothelial dysfunction, microalbuminuria, effects of the anty-hypertensive treatment and of lipid-lowering drugs on the endothelial function

Atherosclerosis and dyslipidemias

Prevention of type 2 diabetes, pre-diabetes and metabolic syndrome

Cell cultures: human mesangial cells, HUVECs, endothelial progenitor cells (EPCs)

Endothelial dysfunction and EPCs in diabetes, pre-diabetes and gestational diabetes

RESEARCH PROJECTS OF INTERNATIONAL RELEVANCE

Italian Microalbuminuria Study.
Between 1988 and 1990, urinary albumin to creatinine concentration ratio (A/C) was measured in 3,636 adult out-patients with IDDM of more than 3 years duration throught Italy with the aim to explore prevalence of microalbuminuria and relationships with blood pressure and glycaemic control.

EURODIAB IDDM Complication Study.
A cross sectional survey of 3250 people with IDDM in 29 centres in Europe has been funded by the EC in 1989-91.
In that study, the EURODIAB Study Group demonstrated several unique findings about the complications of type 1 diabetes mellitus.

EURODIAB PCS (prospective Complication Study).
The EURODIAB IDDM Complications Study Group have realized the follow-up the original participants of the EURODIAB study 5-6 years after the baseline examinations. A centralised information system (CIS) has been designed and implemented by the co-ordinating centre to assist all centres in communicating each other.

EURODIAB controlled trial of lisinopril in insulin dependent diabetes (EUCLID).
The EURODIAB controlled trial of lisinopril in insulin dependent diabetes (EUCLID) was a double-blind, randomised, parallel-design clinical trial of lisinopril and placebo in 18 European centres. The aim was to assess whether early stage intervention in patients without hypertension would limit progression of renal disease, and whether this effect differed according to degree of albuminuria.

IDNT: Irbesartan Diabetic Nephropathy Trial.
The role of blockade of the renin–angiotensin system in type II diabetic patients was not defined at that time. The Collaborative Study Group has initiated the Irbesartan Type II Diabetic Nephropathy Trial (IDNT), exploring the effect of the angiotensin II receptor antagonist irbesartan on progression of renal disease and mortality in type II diabetic patients with overt nephropathy and hypertension.

Effect of Sulodexide in patients with type 2 diabetes and Microalbuminuria.
& Effects of Sulodexide in patients with Overt Type 2 Diabetic Nephropathy.
A multicenter placebo-controlled double-blinded study to determine the effect of sulodexide on urine albumin excretion in patients with type 2 diabetes and microabuminuria (Sun-MICRO) and a randomized, double-blind, placebo-controlled, sulodexide macroalbuminuria (Sun-MACRO) trial, to evaluate the renoprotective effects of sulodexide in patients with type 2 diabetes, renal impairment, and significant proteinuria already receiving maximal therapy with angiotensin II receptor blockers.

EU Project DE-PLAN (Prevention using Lifestyle, Physical Activity and Nutritional Intervention).
This project aimed at addressing the development of national community-based T2D prevention programmes systematically throughout European countries. Therefore the objectives for the proposed project were to assess the T2D risk in European populations and implement and evaluate a lifestyle intervention programme to prevent T2D in high-risk individuals.

ALTITUDE - Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints.
This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. In a double-blind fashion, 8561 patients to aliskiren or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker.

ePREDICE (Early Prevention of Diabetes Complications in Europe)
To assess the long-term effects of different therapeutic regimens, both pharmacological and lifestyle interventions, for the early prevention of diabetic complications in people with intermediate hyperglycaemia (IFG or IGT) and screen-detected diabetes (SD-T2D).

Dapagliflozin DERIVE Study – D1690C00024 – A multicenter, double-blind, placebo-controlled, phase III trial to evaluate the glycaemic efficacy and renal safety of dapagliflozin in patients with type 2 diabertes mellitus with moderate renal impairment (CKD 3A) who heve inadequate glycemic control.
Primary objective: change in HbA1c vs placebo
Secondary objectives: change in body weight, fasting plasma glucose and systolic blood pressure
Safety objectives: change in eGFR
Exploratory objectives: change in UACR, change in UACR category, and several others.

RESEARCH PROJECTS OF INTERNATIONAL RELEVANCE

GENFIEV (GENetics, pathoPHYsiology and EVolution of type 2 diabetes) study
A multicenter, nationwide, Italian study designed to recruit individuals at risk for developing type 2 diabetes mellitus (T2DM) in the attempt to define phenotypic and genotypic features that may allow more accurate identication of high-risk subjects.
Opportunistic recruitment was adopted by screening individuals referred to diabetes clinics because of their potential risk of T2DM.
Nine centers across Italy participated in the study.

RIACE (Renal Insufficiency and Cardiovascular Events)
An observational, multicenter, prospective cohort study on the impact of estimated glomerular filtration rate (eGFR) on CVD morbidity and mortality in type 2 diabetes.
The RIACE cohort consists of 15,933 Caucasian patients with type 2 diabetes, attending consecutively 19 hospital-based Diabetes Clinics of the National Health Service throughout Italy in years 2007-2008. Follow-up of the whole cohort is currently ongoing.

MEMBERSHIP OF SXCIENTIC SOCIETY

SID: Società Italiana di Diabetologia

EASD: European Association for the Study of Diabetes

EDNSG: European Diabetic Nephropathy Study Group

• REVIEWER FOR

Acta Diabetologica
American Journal of Hypertension
BMC Nephrology
BMJ Open
Clinical Chemistry and Laboratory Medicine
Clinical Medicine & Research
Current Medical Research & Opinion
Diabetes and Its Complications

Diabetes/Metabolism Research and Reviews
Diabetes Research and Clinical Practice
Diabetic Medicine
Endocrine Research
European Journal of Clinical Investigation
International Journal of Endocrinology
Journal of Endocrinological Investigation
Journal of Hypertension
Journal of Internal Medicine
Nephrology Dialysis Transplantation
Nutrition, Metabolism and Cardiovascular Disease
PLOS ONE
Postgraduate Medicine
Vascular Pharmacology

PUBLICATIONS

More than 270 papers on national/international journals (147 publications recorded by PubMed).

Furthermore, listed in PubMed, 81 publications as collaborator of EURODIAB IDDM Complications Study and EURODIAB PCS (EURODIAB Prospective Complications Study); 5 as collaborator of EUCLID Study (EURODIAB Controlled Trial of Lisinopril in IDDM); 21 as collaborator of IDNT Study (Irbesartan Diabetic Nephropathy Trial); 3 as collaborator of GENFIEV Study (GENetics, pathoPHYsiology and EVolution of type 2 diabetes); 2 as collaborator of IMSG (Italian Microalbuminuria Study Group); 1 as collaborator of TOSCA.IT (Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial).


More than 500 abstracts or proceedings presented at National and International Meetings.

ResearchID: K-3429-2018;

ORCID: 0000-0002-2834-4847

Pisa, November 16, 2018

SIGNATURE
Giuseppe Penno



LIST OF PUBLICATIONS

A – Listed in PubMed

1. Zusi C, Trombetta M, Bonetti S, Dauriz M, Boselli ML, Trabetti E, Malerba G, **Penno G**, Zoppini G, Bonora E, Solini A, Bonadonna RC. A renal genetic risk score (GRS) is associated with kidney dysfunction in people with type 2 diabetes. Diabetes Res Clin Pract. 2018 Oct;144:137-143. **IF: 2.548**

2. Fadini GP, Solini A, Manca ML, **Penno G**, Gatti A, Anichini R, Del Prato S, Avogaro A; DARWIN-T2D Network. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13508. [Epub ahead of print] **IF: 5.980**

3. **Penno G**, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Scardapane M, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia 2018 Jul 21. **IF: 6.023**

4. Lucchesi D, Popa SG, Sancho V, Giusti L, Garofolo M, Daniele G, Pucci L, Miccoli R, **Penno G**, Del Prato S. Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol 2018; 17: 78. **IF: 5.235**

5. Garofolo M, Russo E, Miccoli R, Lucchesi D, Giusti L, Sancho-Bornez V, Daniele G, Del Prato S, **Penno G**. Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. J Diabetes Complications 2018; 32: 550-557. **IF: 2.792**

6. Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A, **Penno G**, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. Diabetes Obes Metab. 2018 Mar 26. doi: 10.1111/dom.13306. [Epub ahead of print]. **IF: 5.980**

7. **Penno G**, Solini A, Bonora E, Orsi E, Fondelli C, Zerbini G, Trevisan R, Vedovato M, Cavalot F, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetol. 2018 Mar 24. doi: 10.1007/s00592-018-1133-z. [Epub ahead of print]. **IF: 3.126**

8. Sancho V, Daniele G, Lucchesi D, Lupi R, Ciccarone A, **Penno G**, Bianchi C, Dardano A, Miccoli R, Del Prato S. Metabolic regulation of GLP-1 and PC1/3 in pancreatic alpha-cell line. PLoS One. 2017 Nov 9; 12(11): e0187836. **IF: 2.766**

9. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Collaborators: Vaccaro O, Masulli M, Nicolucci A, Maggioni AP, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Riccardi G, Boemi M, D'Angelo F, Giansanti R, Tanase L, Lanari L, Testa I, Ricci L, Pancani F, Ranchelli A, Vagheggi P, Scatona A, Fontana L, Giorgino F, Laviola L, Tarantino L, Ippolito C, Gigantelli V, Manicone M, Conte E, Trevisan R, Scaranna C, Rota R, Corsi A, Dodesini AR, Reggiani GM, Montesi

L, Mazzella N, Forlani G, Caselli C, Di Luzio R, Mazzotti A, Aiello A, Barrea A, Musto A, D'Amico F, Squatrito S, Sinagra T, Longhitano S, Trowpea V, Sparti M, Italia S, Lisi E, Grasso G, Pezzino V, Insalaco F, Gnasso A, Carallo C, Scicchitano C, De Franceschi MS, Santini C, Mazzotti A, Caselli C, Calbucci G, Ripani R, Corsi L, Cuneo G, Corsi S, Giorda CB, Romeo F, Lesina A, Comoglio M, Bonetto C, Robusto A, Nada E, Asprino V, Cetraro R, Impieri M, Lucchese G, Donnarumma G, Tizio B, Clemente G, Lenza L, Paraggio P, Tomasi F, Zamboni C, Dozio N, Scalambra E, Mannucci E, Lamanna C, Cignarelli M, Macchia O, Fariello S, Sorrentino MR, Franzetti I, Radin R, Cordera R, Annunziata F, Bonabello LA, Durante A, Dolcino M, Gallo F, Mazzucchelli C, Aleo A, Melga P, Briatore L, Maggi D, Storace D, Cecoli F, Antenucci D, D'Ugo E, Pupillo M, Baldassarre MPA, Salvati F, Minnucci A, De Luca A, Zugaro A, Santarelli L, Bosco A, Petrella V, La Verghetta GG, Iannarelli R, De Gregorio A, D'Andrea S, Giuliani AE, Polidoro WL, Sperandio A, Sciarretta F, Pezzella A, Buzzetti R, Carlone A, Potenziani S, Venditti C, Foffi C, Carbone S, Cipolloni L, Moretti C, Leto G, Serra R, Petrachi F, Romano I, Di Cianni G, Lacaria E, Russo L, Goretti C, Sannino C, Gregori G, Dolci M, Bruselli L, Mori ML, Baccetti F, Del Freo M, Fontana L, Di Benedetto A, Cucinotta D, Giunta L, Ruffo MC, Cannizzaro D, Pintaudi B, Perrone G, Pata P, Ragonese F, Lettina G, Mancuso T, Coppolino A, Piatti PM, Monti L, Stuccillo M, Lucotti P, Setola M, Crippa GV, Loi C, Oldani M, Bottalico ML, Pellegata B, Bonomo M, Menicatti LSM, Resi V, Bertuzzi F, Disoteo EO, Pizzi G, Rivellese AA, Annuzzi G, Capaldo B, Nappo R, Auciello SM, Turco AA, Costagliola L, Iovine C, Corte GD, Vallefuoco P, Nappi F, Vitale M, Cocozza S, Ciano O, Massimino E, Garofalo N, Avogaro A, Vedovato M, Guarneri G, Lapolla A, Fedele D, Sartore G, Chilelli NC, Burlina S, Bonsembiante B, Giordano C, Galluzzo A, Torregrossa V, Dall'Aglio E, Mancastroppa G, Arsenio L, Cioni F, Caronna S, Papi M, Babini M, Perriello G, Santeusanio F, Calagreti G, Timi A, Tantucci A, Marino C, Consoli A, Ginestra F, Di Biagio R, Taraborelli M, Del Prato S, Miccoli R, Bianchi C, Garofolo M, Politi KS, **Penno G**, Zavaroni D, Livraga S, Calzoni F, Mancastroppa GLF, Anichini R, Corsini E, Tedeschi A, Gaglianò MS, Ippolito G, Salutini E, Citro G, Cervellino F, Natale M, Salvatore V, Zampino A, Sinisi R, Calabrese M, Arcangeli A, Zogheri A, Guizzotti S, Longo R, Di Bartolo P, Caselli C, Pellicano F, Scolozzi P, Termine S, Luberto A, Ballardini G, Babini AC, Ripani R, Trojani C, Mazzuca P, Bruglia M, Ciamei M, Genghini S, Zannoni C, Pugliese G, Vitale M, Rangel G, Salvi L, Zappaterreno A, Cordone S, Simonelli P, Meggiorini M, Frasheri A, Di Pippo C, Maglio C, Mazzitelli G, Lauro D, Rinaldi ME, Galli A, Romano M, D'Angelo P, Leotta S, Suraci C, De Cosmo S, Bacci S, Palena AP, Genovese S, Mancino M, Rondinelli M, Capone F, Calabretto E, Bulgheroni M, Bucciarelli L, Dotta F, Ceccarelli E, Fondelli C, Santacroce C, Guarino E, Nigi L, Lalli C, Di Vizia G, Scarponi M, Montani V, Di Bernardino P, Romagni P, Dolcetti K, Cannarsa E, Forte E, Potenziani S, Tamburo L, Fornengo P, Perin PC, Prinzis T, Gruden G, Bruno G, Zucco C, Perotta M, Marena S, Monsignore S, Panero F, Ponzi F, Bossi AC, Carpinteri R, Casagrande ML, Coletti MF, Menicatti LSM, Balini A, Filopanti M, Madaschi S, Pulcina A, Grimaldi F, Tonutti L, Venturini G, Agus S, Pagnutti S, Guidotti F, Cavarape A, Casagrande ML, Bonora E, Cigolini M, Pichiri I, Brangani C, Fainelli G, Tomasetto E, Zoppini G, Galletti A, Perrone D, Capra C, Bianchini F, Ceseri M, Di Nardo B, Sasso E, Bartolomei B, Suliman I, Fabbri G, Romano G, Maturo N, Nunziata G, Capobianco G, De Simone G, Villa V, Rota G, Pentangelo C, Carbonara O, Caiazzo G, Cutolo M, Sorrentino T, Mastrilli V, Amelia U, Masi S, Corigliano G, Gaeta I, Armentano V, Calatola P, Capuano G, Angiulli B, Auletta P, Petraroli E, Iodice CE, Agrusta M. Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. **IF: 19.313**

10. **Penno G**, Russo E, Garofolo M, Daniele G, Lucchesi D, Giusti L, Sancho Bornez V, Bianchi C, Dardano A, Miccoli R, Del Prato S. Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. Diabetologia. 2017 Oct;60(10):2123-2125. **IF: 6.023**

11. Prudente S, Di Paola R, Pezzilli S, Garofolo M, Lamacchia O, Filardi T, Mannino GC, Mercuri L, Alberico F, Scarale MG, Sesti G, Morano S, **Penno G**, Cignarelli M, Copetti M, Trischitta V. Pharmacogenetics of oral antidiabetes drugs: evidence for diverse signals at the IRS1 locus. Pharmacogenomics J. 2017 Jul 11. doi: 10.1038/tpj.2017.32. [Epub ahead of print] **IF: 2.302**

12. Giusti L, Gabriele M, **Penno G**, Garofolo M, Longo V, Del Prato S, Lucchesi D, Pucci L. A Fermented Whole Grain Prevents Lipopolysaccharides-Induced Dysfunction in Human Endothelial Progenitor Cells. Oxid Med Cell Longev. 2017;2017:1026268. doi: 10.1155/2017/1026268. Epub 2017 Mar 13.

13. **Penno G**, Russo E, Garofolo M, Daniele G, Lucchesi D, Giusti L, Sancho Bornez V, Bianchi C, Dardano A, Miccoli R, Del Prato S. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia. 2017 Jun;60(6):1102-1113. **IF: 6.023**

14. Lamacchia O, Fontana A, Pacilli A, Copetti M, Fariello S, Garofolo M, **Penno G**, Trischitta V, De Cosmo S, Cignarelli M.On the non-linear association between serum uric acid levels and all-cause mortality rate in patients with type 2 diabetes mellitus. Atherosclerosis. 2017 May; 260: 20-26. **IF: 4.467**

15. Russo R, Barsanti L, Evangelista V, Frassanito AM, Longo V, Pucci L, **Penno G**, Gualtieri P. *Euglena gracilis* paramylon activates human lymphocytes by upregulating pro-inflammatory factors. Food Sci Nutr. 2016 May 20; 5(2): 205-214. **IF: 1.550**

16. Buzzetti R, Prudente S, Copetti M, Dauriz M, Zampetti S, Garofolo M, **Penno G**, Trischitta V. Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications: A position statement of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis. 2017 Feb; 27(2): 99-114. **IF: 3.318**

17. Prudente S, Di Paola R, Copetti M, Lucchesi D, Lamacchia O, Pezzilli S, Mercuri L, Alberico F, Giusti L, Garofolo M, **Penno G**, Cignarelli M, De Cosmo S, Trischitta V. The rs12917707 polymorphism at the UMOD locus and glomerular filtration rate in individuals with type 2 diabetes: evidence of heterogeneity across two different European populations. Nephrol Dial Transplant. 2017 Oct 1;32(10):1718-1722. **IF: 4.600**

18. **Penno G**, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutr Metab Cardiovasc Dis. 2016 May; 26(5): 361-73. **IF: 3.318**

19. Solini A, Manca ML, **Penno G**, Pugliese G, Cobb JE, Ferrannini E. Prediction of Declining Renal Function and Albuminuria in Patients With Type 2 Diabetes by Metabolomics. J Clin Endocrinol Metab. 2016 Feb; 101(2): 696-704. **IF: 5.789**

20. Romano M, Lacaria E, Battini L, Aragona M, Bianchi C, **Penno G**, Del Prato S, Bertolotto A. How much weight are women gaining during pregnancy? An Italian cohort study. Gynecol Endocrinol. 2015; 31(12): 942-4. **IF: 1.333**

21. **Penno G**, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L, Orsi E, Pugliese G; Renal Insufficiency Cardiovascular Events (RIACE) Study Group. Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetol. 2015 Oct; 52(5): 971-81. **IF: 2.399**

22. Salutini E, Bianchi C, Santini M, Dardano A, Daniele G, **Penno G**, Miccoli R, Del Prato S. Access to emergency room for hypoglycaemia in people with diabetes. Diabetes Metab Res Rev. 2015 Oct; 31(7): 745-51. **IF: 3.553**

23. **Penno G**, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Gruden G, Lamacchia O, Pontiroli AE, Arosio M, Orsi E, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS One. 2015 May 5; 10(5): e0125512. **IF: 3.234**

24. Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD; EURODIAB Prospective Complications Study Group. Collaborators: Karamanos B, Kofinis A, Petrou K, Giorgino F, Picca G, Angarano A, de Pergola G, Laviola L, Giorgino R, Ionescu-Tirgoviste C, Coszma A, Guja C, Songini M, Casu A, Pedron M, Pintus S, Fossarello M, Ferriss J, Grealy G, O'Keefe D, Toeller M, Arden C, Rottiers R, Tuyttens C, Priem H, Ebeling P, Kylliäinen M, Koivisto V, Idzior-Walus B,

Sieradzki J, Cyganek K, Solnica B, Lemkes H, Lemkes-Stuffken J, Nunes-Correa J, Rogado M, Gardete-Correia L, Cardoso M, Silva A, Boavida J, Marques M, Michel G, Wirion R, Cardillo S, Pozza G, Mangili R, Asnaghi V, Standl E, Schaffler B, Brand H, Harms A, Soussan D, Verier-Mine O, Fallas P, Fallas M, Fuller J, Holloway J, Asbury L, J D, Cathelineau G, Bouallouche A, Cathelineau B, Santeusanio F, Rosi G, D'Alessandro V, Cagini C, Bottini P, Reboldi G, Navalesi R, **Penno G**, Bandinelli S, Miccoli R, Nannipieri M, Ghirlanda G, Saponara C, Cotroneo P, Manto A, Minnella A, Ward J, Tesfaye S, Eaton S, Mody C, Borra M, Perin P, Giunti S, Grassi G, Pagano G, Porta M, Sivieri R, Vitelli F, Veglio M, Papazoglou N, Manes G, Muggeo M, Iagulli M, Cacciatori V, Irsigler K, Abrahamian H, Walford S, Sinclair J, Hughes S, McLelland V, Ward J, Roglic G, Metelko Z, Pepeonik Z, Vrhovac V. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol. 2015 Mar 10;14:31. **IF: 4.020**

25. Biancofiore G, Bindi ML, Miccoli M, Cerutti E, Lavezzo B, Pucci L, Bisà M, Esposito M, Meacci L, Mozzo R, Stratta C, **Penno G**, Baggiani A, Filipponi F. Intravenous fenoldopam for early acute kidney injury after liver transplantation. J Anesth. 2014. [Epub ahead of print] **IF: 1.117**

26. Lucchesi D, Russo R, Gabriele M, Longo V, Del Prato S, **Penno G**, Pucci L. Grain and bean lysates improve function of endothelial progenitor cells from human peripheral blood: involvement of the endogenous antioxidant defenses. PLoS One. 2014; 9: e109298. **IF: 3.534**

27. Solini A, Zoppini G, Orsi E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Arosio M, Baroni MG, **Penno G**, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications. J Hypertens. 2014; 32: 2401-2410. **IF: 4.222**

28. Dell'Omo G, **Penno G**, Pucci L, Lucchesi D, Del Prato S, Pedrinelli R. Q192R Paraoxonase (PON)1 Polymorphism, Insulin Sensitivity, and Endothelial Function in Essential Hypertensive Men. Clin Med Insights Cardiol. 2014; 8: 57-62.

29. Prudente S, Morini E, Lucchesi D, Lamacchia O, Bailetti D, Mercuri L, Alberico F, Copetti M, Pucci L, Fariello S, Giusti L, Cignarelli M, **Penno G**, De Cosmo S, Trischitta V. IRS1 G972R missense polymorphism is associated with failure to oral antidiabetes drugs in white patients with type 2 diabetes from Italy. Diabetes. 2014; 63: 3135-3140. **IF: 8.474**

30. Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, **Penno G**; RIACE Study Group. Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutr Metab Cardiovasc Dis. 2014; 24: 815-822. **IF: 3.875**

31. Dardano A, **Penno G**, Del Prato S, Miccoli R. Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY). 2014; 6: 187-206. **IF: 7.666**

32. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, **Penno G**; RIACE Study Group. Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2014; 13: 59. . **IF: 3.710**

33. Frontoni S, Solini A, Fioretto P, Natali A, Zuccalà A, Cosentino F, **Penno G**; Italian Society of Diabetology (SID)-Study Group on Diabetes, Hypertension and the Kidney. The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: a neutral viewpoint. Nutr Metab Cardiovasc Dis. 2014; 24: 577-584. **IF: 3.875**

34. De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, Ceriello A, Russo G, Nicolucci A, Giorda C, Viazzi F, Pontremoli R; AMD-Annals Study Group. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Among 1098 collaborators: Del Prato S, Miccoli R, Bianchi C, **Penno G**, Venditti F. Nephrol Dial Transplant. 2014; 29: 657-662. **IF: 3.488**

35. De Cosmo S, Prudente S, Lamacchia O, Pucci L, Lucchesi D, Mendonca C, Bailetti D, Copetti M,

Pellegrini F, Cignarelli M, **Penno G**, Doria A, Trischitta V. The IRS1 G972R polymorphism and glomerular filtration rate in patients with type 2 diabetes of European ancestry. Nephrol Dial Transplant. 2013; 28: 3031-3034. **IF: 3.488**

36. Solini A, **Penno G**, Bonora E, Fondelli C, Orsi E, Trevisan R, Vedovato M, Cavalot F, Cignarelli M, Morano S, Ferrannini E, Pugliese G; Renal Insufficiency and Cardiovascular Events Study Group. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. J Am Geriatr Soc. 2013; 61: 1253-1261. **IF: 4.216**

37. **Penno G**, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, Morano S, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2013; 12: 98. **IF: 3.710**

38. Russo E, **Penno G**, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes. 2013; 6: 161-70.

39. **Penno G**, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) study, group. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med. 2013; 274: 176-191. **IF: 5.785**

40. Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo G, Leonetti F, Bonadonna RC, Del Prato S; GENFIEV Investigators. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired ß-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. Collaborators: Cignarelli A, Cerrelli F, Moscatiello S, Gnasso A, Irace C, Consoli A, Taraborelli M, Formoso G, Mori M, Gregori G, Trovati M, Bonomo K, **Penno G**, Agostini A, Anichini R, De Bellis A, Bracaglia D, Perna M, Calabria M, Zappaterreno S, Barchetta I, Taverni A, Giaccari A, Antonelli A, Calì A. J Clin Endocrinol Metab. 2013; 98: 2100-2105. **IF: 6.,310**

41. **Penno G**, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care. 2013; 36: 2301-2310. **IF: 8.570**

42. **Penno G**, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, Gruden G, Cavalot F, Laviola L, Morano S, Nicolucci A, Pugliese G; for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Rate and Determinants of Association Between Advanced Retinopathy and Chronic Kidney Disease in Patients With Type 2 Diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care. 2012; 35: 2317-2323. **IF: 7.735**

43. Pugliese G, Solini A, Zoppini G, Fondelli C, Zerbini G, Vedovato M, Cavalot F, Lamacchia O, Buzzetti R, Morano S, Nicolucci A, **Penno G**; for the Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Res Clin Pract. 2012; 98: 329-337. **IF: 2.754**

44. Bruno RM, Ghiadoni L, **Penno G**, Taddei S, Del Prato S. Might hypovitaminosis D aggravate endothelial dysfunction-related increases in arterial stiffness seen in patients with hypertension and type 2 diabetes? Reply to Boucher BJ [letter]. Diabetologia. 2012; 55: 3142-3143. **IF: 6.814**

45. Giannarelli C, Bianchini E, Bruno RM, Magagna A, Landini L, Faita F, Gemignani V, **Penno G**, Taddei S, Ghiadoni L. Local carotid stiffness and intima-media thickness assessment by a novel ultrasound-based system in essential hypertension. Atherosclerosis. 2012; 223: 372-377. **IF: 3.794**



46. De Cosmo S, Prudente S, Lamacchia O, Lucchesi D, Shah H, Mendonca C, Pucci L, Mercuri L, Gervino EV, Hauser TH, Bailetti D, **Penno G**, Cignarelli M, Doria A, Trischitta V. The 9p21 coronary artery disease locus and kidney dysfunction in patients with Type 2 diabetes mellitus. Nephrol Dial Transplant. 2012; 27: 4411-4413. **IF: 3.396**

47. Bruno RM, **Penno G**, Daniele G, Pucci L, Lucchesi D, Stea F, Landini L, Cartoni G, Taddei S, Ghiadoni L, Del Prato S. Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. Diabetologia. 2012; 55: 1847-1855. **IF: 6.814**

48. Solini A, **Penno G**, Bonora E, Fondelli C, Orsi E, Arosio M, Trevisan R, Vedovato M, Cignarelli M, Andreozzi F, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012; 35: 143-149. **IF: 8.087**

49. **Penno G**, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011; 29: 1802-9. **IF: 4.021**

50. **Penno G**, Pucci L, Lucchesi D, Lencioni C, Iorio MC, Vanacore R, Storti E, Resi V, Di Cianni G, Del Prato S. Circulating endothelial progenitor cells in women with gestational alterations of glucose tolerance. Diab Vasc Dis Res. 2011; 8: 202-210. **IF: 2.116**

51. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Giorgino F, Cavalot F, Pontiroli AE, Baroni MG, Morano S, Nicolucci A, **Penno G**. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. Atherosclerosis. 2011; 218: 194-199. **IF: 3.794**

52. Miccoli R, **Penno G**, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. Diabetes Care. 2011; 34 Suppl 2: S231-S235. **IF: 8.087**

53. Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A, **Penno G**; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. Nephrol Dial Transplant. 2011; 26: 3950-3954. **IF: 3.396**

54. Felice F, Lucchesi D, di Stefano R, Barsotti MC, Storti E, **Penno G**, Balbarini A, Del Prato S, Pucci L. Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells: evidence for differential glutathione peroxidase-1 expression. Microvasc Res. 2010; 80: 332-338. **IF: 2.828**

55. Bianchi C, **Penno G**, Miccoli R, Del Prato S. Blood glucose control and coronary heart disease. Herz – Cardiovascular Disease. 2010 May; 35: 148-59.

56. Pedrinelli R, Canale ML, Giannini C, Talini E, **Penno G**, Dell'Omo G, Di Bello V. Right ventricular dysfunction in early systemic hypertension: a tissue Doppler imaging study in patients with high-normal and mildly increased arterial blood pressure. J Hypertens. 2010; 28: 615-621. **IF: 4.021**

57. Bianchi C, **Penno G**, Crisci I, Daniele G, Agostini A, Del Prato S, Miccoli R. Serum gamma-glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation. Diabetes Metab Res Rev. 2010; 26: 181-186. **IF: 3.373**

58. Di Bello V, Talini E, Dell'Omo G, Giannini C, Delle Donne MG, Canale ML, Nardi C, Palagi C, Dini FL, **Penno G**, Del Prato S, Marzilli M, Pedrinelli R. Early left ventricular mechanics abnormalities in prehypertension: a two-dimensional strain echocardiography study. Am J Hypertens. 2010; 23: 405-12. **IF: 3.181**



59. Bianchi C, Miccoli R, Daniele G, **Penno G**, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care. 2009; 32 Suppl 2: S342-8. Review. **IF: 8.087**

60. Del Prato S, **Penno G**, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care. 2009; 32 Suppl 2: S217-22. Review. **IF: 8.087**

61. **Penno G**, Pucci L, Dell'Omo G, Lucchesi D, Miccoli R, Del Prato S, Solini A, Pedrinelli R. Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. Am J Hypertens. 2009; 22: 1007-13. **IF: 3.181**

62. Dell'Omo G, **Penno G**, Pucci L, Lucchesi D, Del Prato S, Pedrinelli R. Lack of association between TGF-beta-1 genotypes and microalbuminuria in essential hypertensive men. Nephrol Dial Transplant. 2009; 24: 1864-1869. **IF: 3.396**

63. Dell'Omo G, **Penno G**, Del Prato S, Mariani M, Pedrinelli R. Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. J Hum Hypertens. 2009; 23: 332-338. **IF: 2.802**

64. Bianchi C, **Penno G**, Daniele G, Russo E, Giovannitti MG, Del Prato S, Miccoli R. The metabolic syndrome is related to albuminuria in Type 2 diabetes. Diabet Med. 2008 Dec; 25: 1412-1418. **IF: 2.902**

65. Bianchi C, **Penno G**, Del Prato S, Miccoli R. Serum gamma-glutamyltransferase is not associated to peripheral arterial disease in type 2 diabetic patients: Cross-sectional findings. Atherosclerosis. 2009; 203: 49-50. **IF: 3.794**

66. Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, **Penno G**, Pucci L, Taddei S, Del Prato S, Salvetti A. Peripheral wave reflection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome. J Hypertens. 2008; 26: 1216-1222. **IF: 4.021**

67. Volpe L, Cuccuru I, Lencioni C, Napoli V, Ghio A, Fotino C, Bertolotto A, **Penno G**, Benzi L, Del Prato S, Di Cianni G. Early subclinical atherosclerosis in women with previous gestational diabetes mellitus. Diabetes Care. 2008; 31: e32. **IF: 8.087**

68. Bianchi C, Miccoli R, **Penno G**, Del Prato S. Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care. 2008; 31 Suppl 2: S208-14. Review. **IF: 8.087**

69. Bianchi C, **Penno G**, Daniele G, Benzi L, Del Prato S, Miccoli R. Optimizing management of metabolic syndrome to reduce risk: focus on life-style. Intern Emerg Med. 2008; 3: 87-98. Epub 2008 Feb 13. Review. **IF: 2.057**

70. Fiorito M, Torrente I, De Cosmo S, Guida V, Colosimo A, Prudente S, Flex E, Menghini R, Miccoli R, **Penno G**, Pellegrini F, Tassi V, Federici M, Trischitta V, Dallapiccola B. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity (Silver Spring). 2007; 15: 2889-2895. **IF: 4.284**

71. Ghiadoni L, **Penno G**, Giannarelli C, Plantinga Y, Bernardini M, Pucci L, Miccoli R, Taddei S, Salvetti A, Del Prato S. Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. Hypertension. 2008; 51: 440-445. **IF: 6.207**

72. Dell'Omo G, **Penno G**, Del Prato S, Pedrinelli R. Doxazosin in metabolically complicated hypertension. Expert Rev Cardiovasc Ther. 2007; 5: 1027-1035. Review.

73. Del Prato S, Bianchi C, Miccoli R, **Penno G**. Pharmacological intervention in prediabetes: considering the risks and benefits. Diabetes Obes Metab. 2007; 9 Suppl 1: 17-22. Review. **IF: 3.379**

74. Talini E, Di Bello V, Bianchi C, Palagi C, Delle Donne MG, **Penno G**, Nardi C, Canale ML, Del Prato S,

Mariani M, Miccoli R. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study. Atherosclerosis. 2008; 197: 346-354. **IF: 3.794**

75. Fadini GP, Pucci L, Vanacore R, Baesso I, **Penno G**, Balbarini A, Di Stefano R, Miccoli R, de Kreutzenberg S, Coracina A, Tiengo A, Agostini C, Del Prato S, Avogaro A. Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia. 2007; 50: 2156-2163. **IF: 6.814**

76. Dell'Omo G, **Penno G**, Pucci L, Fotino C, Lucchesi D, Del Prato S, Pedrinelli R. Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men. J Hypertens. 2007; 25: 1389-1395. **IF: 4.021**

77. Bianchi C, **Penno G**, Pancani F, Civitelli A, Piaggesi A, Caricato F, Pellegrini G, Del Prato S, Miccoli R. Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 78: 246-253. **IF: 2.754**

78. Bianchi C, **Penno G**, Romero F, Del Prato S, Miccoli R. Treating the metabolic syndrome. Expert Rev Cardiovasc Ther. 2007; 5: 491-506. Review.

79. Bianchi C, **Penno G**, Malloggi L, Barontini R, Corfini M, Giovannitti MG, Di Cianni G, Del Prato S, Miccoli R. Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. Nutr Metab Cardiovasc Dis. 2008; 18: 31-38. **IF: 3.731**

80. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, **Penno G**, Del Prato S, Paniga S, Cicero AF. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab. 2007; 33: 129-134. **IF: 2.411**

81. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, Miccoli R, Del Prato S, **Penno G**. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007; 53: 480-488. **IF: 7.905**

82. Di Cori A, Di Bello V, Miccoli R, Talini E, Palagi C, Delle Donne MG, **Penno G**, Nardi C, Bianchi C, Mariani M, Del Prato S, Balbarini A. Left ventricular function in normotensive young adults with well-controlled type 1 diabetes mellitus. Am J Cardiol. 2007; 99: 84-90. **IF: 3.368**

83. Dell'Omo G, **Penno G**, Pucci L, Lucchesi D, Fotino C, Del Prato S, Pedrinelli R. ACE gene insertion/deletion polymorphism modulates capillary permeability in hypertension. Clin Sci (Lond). 2006; 111: 357-64. **IF: 4.317**

84. **Penno G**, Miccoli R, Pucci L, Del Prato S. The metabolic syndrome. Beyond the insulin resistance syndrome. Pharmacol Res. 2006; 53: 457-68. Review. **IF: 4.436**

85. Pedrinelli R, Dell'Omo G, **Penno G**, Di Bello V, Pucci L, Fotino C, Lucchesi D, Del Prato S, Dal Fiume C, Barlassina C, Cusi D. Alpha-adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. J Hypertens. 2006; 24 (5): 931-7. Erratum in: J Hypertens. 2006; 24: 931-937. **IF: 4.021**

86. Biancofiore G, Pucci L, Cerutti E, **Penno G**, Pardini E, Esposito M, Bindi L, Pelati E, Romanelli A, Triscornia S, Salvadorini MP, Stratta C, Lanfranco G, Pellegrini G, Del Prato S, Salizzoni M, Mosca F, Filipponi F. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl. 2006; 12: 285-291. **IF: 3.386**

87. Dell'Omo G, **Penno G**, Del Prato S, Pedrinelli R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J Cardiovasc Pharmacol Ther. 2005; 10: 265-272. **IF: 1.753**

88. Miccoli R, Bianchi C, Odoguardi L, **Penno G**, Caricato F, Giovannitti MG, Pucci L, Del Prato S.

Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis. 2005; 15: 250-254. **IF: 3.731**

89. Pucci L, Chirulli V, Marini S, Lucchesi D, **Penno G**, Gervasi PG, Del Prato S, Longo V. Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. Pharmacol Res. 2005; 51: 561-565. **IF: 4.436**

90. Dell'Omo G, **Penno G**, Pucci L, Pellegrini G, Scotti A, Del Prato S, Pedrinelli R. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis. 2005; 16: 67-73. **IF: 1.237**

91. Pedrinelli R, Dell'Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, **Penno G**. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004; 24: 2414-2419. **IF: 6.370**

92. De Cosmo S, Marucci A, Ciociola E, Di Paola R, Pucci L, **Penno G**, Del Prato S, Piras GP, Trevisan R, Giunti S, Viberti GC, Trischitta V. Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients. Nephrol Dial Transplant. 2004; 19: 2419-24120. **IF: 3.396**

93. Dell'Omo G, **Penno G**, Pucci L, Mariani M, Del Prato S, Pedrinelli R. Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. Atherosclerosis. 2004; 172: 383-389. **IF: 3.794**

94. Pucci L, Lucchesi D, Fotino C, Grupillo M, Miccoli R, **Penno G**, Del Prato S. Integrin Beta 3 PIA1/PIA2 polimorphism does not contribute to complications in both type 1 and type 2 diabetes. G Ital Nefrol. 2003; 20: 461-9.

95. Pucci L, Lucchesi D, Chirulli V, **Penno G**, Johansson I, Gervasi P, Del Prato S, Longo V. Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus. Am J Pharmacogenomics. 2003; 3: 355-358. **IF: 1.710**

96. Pedrinelli R, Dell'Omo G, **Penno G**, Di Bello V, Giorgi D, Pellegrini G, Del Prato S, Mariani M. Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. J Hypertens. 2003; 21: 1163-1169. **IF: 4.021**

97. Dell'Omo G, **Penno G**, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002; 40: 1-8. **IF: 5.434**

98. Pedrinelli R, Dell'Omo G, **Penno G**, Mariani M. Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med. 2001; 6: 257-64. Review. **IF: 1.457**

99. Chaturvedi N, Bandinelli S, Mangili R, **Penno G**, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001; 60: 219-27. **IF: 6.606**

100. Pucci L, Bandinelli S, Pilo M, Nannipieri M, Navalesi R, **Penno G**. Iohexol as a marker of glomerular filtration rate in patients with diabetes: comparison of multiple and simplified sampling protocols. Diabet Med. 2001; 18: 116-20. **IF: 2.902**

101. Mattock MB, Cronin N, Cavallo-Perin P, Idzior-Walus B, **Penno G**, Bandinelli S, Standl E, Kofinis A, Fuller JH; EURODIAB IDDM Complications Study. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med. 2001; 18: 59-67. **IF: 2.902**

102. Pedrinelli R, Dell'Omo G, **Penno G**, Bandinelli S, Giannini D, Balbarini A, Mariani M. Dissociation between microalbuminuria and common carotid thickness in essential hypertensive men. J Hum Hypertens. 2000; 14: 831-5. **IF: 2.802**



103. Dell'Omo G, Bandinelli S, **Penno G**, Pedrinelli R, Mariani M. Simvastatin, capillary permeability, and acetylcholine-mediated vasomotion in atherosclerotic, hypercholesterolemic men. Clin Pharmacol Ther. 2000; 68: 427-34.

104. Pedrinelli R, Dell'Omo G, Bandinelli S, **Penno G**, Mariani M. Transvascular albumin leakage and forearm vasodilatation to acetylcholine in essential hypertension. Am J Hypertens. 2000; 13: 256-61. **IF: 3.181**

105. Pedrinelli R, Dell'Omo G, **Penno G**, Bandinelli S, Bertini A, Di Bello V, Mariani M. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension. 2000; 35 (1 Pt 1): 48-54. **IF: 6.207**

106. Pedrinelli R, **Penno G**, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, Navalesi R, Mariani M. Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension. 1999; 34: 491-5. **IF: 6.207**

107. Nannipieri M, **Penno G**, Pucci L, Colhoun H, Motti C, Bertacca A, Rizzo L, De Giorgio L, Zerbini G, Mangili R, Navalesi R. Pronatriodilatin gene polymorphisms, microvascular permeability, and diabetic nephropathy in type 1 diabetes mellitus. J Am Soc Nephrol. 1999; 10: 1530-41. **IF: 9.663**

108. Bertolotto A, Bandinelli S, Ruocco L, Lo Faro A, **Penno G**, Navalesi R. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis. 1999; 143: 455-7. **IF: 3.794**

109. Pedrinelli R, Dell'Omo G, Giampietro O, Giorgi D, Di Bello V, Bandinelli S, **Penno G**, Mariani M. Dissociation between albuminuria and insulinaemia in hypertensive and atherosclerotic men. J Hum Hypertens. 1999; 13: 129-34. **IF: 2.802**

110. **Penno G**, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong LA, Fuller JH. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 1998; 47: 1507-11. **IF: 8.286**

111. Pedrinelli R, **Penno G**, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, Nannipieri M, Navalesi R, Mariani M. Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. Hypertension. 1998; 32: 318-23. **IF: 6.207**

112. Pucci L, Bandinelli S, **Penno G**, Nannipieri M, Rizzo L, Navalesi R. Iohexol plasma clearance in determining glomerular filtration rate in diabetic patients. Ren Fail. 1998; 20: 277-284. **IF: 0.824**

113. Mattei P, Arzilli F, Giovannetti R, **Penno G**, Arrighi P, Taddei S, Salvetti A. Microalbuminuria and renal haemodynamics in essential hypertension. Eur J Clin Invest. 1997; 27: 755-60. **IF : 2.736**

114. Nannipieri M, **Penno G**, Rizzo L, Pucci L, Bandinelli S, Mattei P, Taddei S, Salvetti A, Navalesi R. Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension. Diabetes Care. 1997; 20: 1019-26. **IF: 8.087**

115. Navalesi R, Rizzo L, Nannipieri M, Rapuano A, Bandinelli S, Pucci L, Bertacca A, **Penno G**. Hypertension and diabetes. Ann Ital Med Int. 1995; 10 Suppl: 121S-129S. Review.

116. Nannipieri M, Rizzo L, Rapuano A, Pilo A, **Penno G**, Navalesi R. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care. 1995; 18: 1-9. **IF: 8.087**

117. Giampietro O, **Penno G**, Clerico A, Cruschelli L, Cecere M. How and how long to store urine samples before albumin radioimmunoassay: a practical response. Clin Chem. 1993; 39: 533-6. **IF: 7.905**

118. **Penno G**, Rizzo L, Cecere M, Nannipieri M, Lucchetti A, Rapuano A, Giovannitti G, Miccoli R, Navalesi R, Giampietro O. Microalbuminuria is linked with abnormalities favoring atherosclerosis in type 2 diabetics. Contrib Nephrol. 1993; 101: 127-34. **IF: 1.274**



119. **Penno G**, Clerico A, Cruschelli L, Rigamonti G, Crepaldi G, Navalesi R, Giampietro O. External quality control for radioimmunoassay of urinary albumin in diabetic subjects: a one-year experience. Clin Chem. 1992; 38: 2333-5. **IF: 7.905**

120. Giampietro O, **Penno G**, Clerico A, Cruschelli L, Lucchetti A, Nannipieri M, Cecere M, Rizzo L, Navalesi R. Which method for quantifying "microalbuminuria" in diabetics? Comparison of several immunological methods (immunoturbidimetric assay, immunonephelometric assay, radioimmunoassay and two semiquantitative tests) for measurement of albumin in urine. Acta Diabetol. 1992; 28: 239-45. **IF: 2.784**

121. Giampietro O, Clerico A, **Penno G**, Gregori G, Del Chicca MG, Cionini R, Volpe L, Navalesi R. Endogenous digitalis-like factors (EDLF) in obese individuals: preliminary results. J Nucl Biol Med. 1992; 36: 41-5. **IF: 3.023**

122. Clerico A, **Penno G**, Giampietro O. Albuminuria in the diabetic patient: clinical relevance and methodological features. Minerva Endocrinol. 1991; 16: 157-161. Review. **IF: 0.981**

123. Giampietro O, Cruschelli L, **Penno G**, Navalesi R, Clerico A. More on effects of storage time and temperature on measurement of small concentrations of albumin in urine. Clin Chem. 1991; 37: 591-5. **IF: 7.905**

124. Cruschelli L, Clerico A, **Penno G**, Navalesi R, Giampietro O. Colorimetric versus radioimmunological measurement of glycated and non-glycated serum albumin after affinity chromatography. Acta Diabetol Lat. 1990; 27: 349-56. **IF: 2.784**

125. Di Cianni G, Benzi L, Ciccarone AM, Cecchetti P, Giannarelli R, **Penno G**, Navalesi R. Efficacy of sulfonylurea and sulfonylurea-benfluorex therapy in patients with type 2 diabetes treated with commercial sulfonylurea-biguanide combinations. Clin Ter. 1990; 134: 187-91. **IF: 0.266**

126. Giampietro O, Ferdeghini M, Miccoli R, Gregori G, **Penno G**, Bertoli S, Navalesi R. Inappropriate growth-hormone (GH) response to thyrotropin-releasing hormone (TRH) occurs infrequently in well-regulated diabetes mellitus. Acta Diabetol Lat. 1990; 27: 119-27. **IF: 2.784**

127. Clerico A, Giammattei C, Cecchini L, Lucchetti A, Cruschelli L, **Penno G**, Gregori G, Giampietro O. Exercise-induced proteinuria in well-trained athletes. Clin Chem. 1990; 36: 562-4. **IF: 7.905**

128. Miccoli R, Orlandi MC, Fruzzetti F, Melis GB, Giampietro O, Ricci C, Bertolotto A, Masoni A, **Penno G**, Fioretti P, Navalesi R. Effects of low-dose oral contraceptives on sugar metabolism. Minerva Ginecol. 1989; 41: 441-4.

129. Giampietro O, Lucchetti A, Cruschelli L, Clerico A, Berni R, **Penno G**, Gregori G, Bertoli S, Giordani R, Navalesi R. Measurement of urinary albumin excretion (UAE) in diabetic patients: immunonephelometry versus radioimmunoassay. J Nucl Med Allied Sci. 1989; 33: 252-257.

130. Giampietro O, Clerico A, Cruschelli L, **Penno G**, Navalesi R. Microalbuminuria in diabetes mellitus: more on urine storage and accuracy of colorimetric assays. Clin Chem. 1989; 35: 1560-1562. **IF: 7.905**

131. Miccoli R, Giampietro O, **Penno G**, Odello G, Anichini R, Bertolotto A, Cruschelli L, Bertoli S, Navalesi R. 'Microalbuminuria' in type I (insulin-dependent) diabetic patients with and without retinopathy. Acta Diabetol Lat. 1989; 26: 163-70. **IF: 2.784**

132. Giampietro O, Miccoli R, Clerico A, **Penno G**, Cruschelli L, Palmieri L, Di Palma L, Gregori G, Anichini R, Bertoli S, Navalesi R. Early diagnosis of diabetic nephropathy. Significance and clinical usefulness of albuminuria and enzymuria. Minerva Endocrinol. 1988; 13: 187-201. **IF: 0.981**

133. Tognarelli M, Miccoli R, Giampietro O, Benzi L, Ciccarone A, Giovannitti G, Bertolotto A, **Penno G**, Navalesi R. Effects of guar-pasta on serum lipid levels in obese diabetic and non-diabetic women with

normal lipids. Acta Diabetol Lat. 1988; 25: 243-6. **IF: 2.784**

134. Giampietro O, Miccoli R, Anichini R, **Penno G**, Navalesi R. Short-term vs. overnight urine collection for screening of urinary albumin excretion rate. Diabetes Care. 1988; 11: 509-10. **IF: 8.087**

135. Navalesi R, Giampietro O, Miccoli R, **Penno G**, Gregori G, Tallarigo L. Glucose tolerance and complications of pregnancy in nondiabetic women. N Engl J Med 1987; 316: 1343-1346 (correspondence). **IF: 53.298**

136. Giampietro O, Miccoli R, Ferdeghini M, **Penno G**, Masoni A, Navalesi R. Inappropriate growth hormone response to luteinizing hormone-releasing hormone in diabetes mellitus. Metabolism. 1987; 36: 1149-53. **IF: 2.664**

137. Miccoli R, Odello G, Giampietro O, Marchetti P, Cristofani R, **Penno G**, Meucci G, Navalesi R. Circulating lipid levels and severity of diabetic retinopathy in type I diabetes mellitus. Ophthalmic Res. 1987; 19: 52-56. **IF: 1.561**

138. Tallarigo L, Giampietro O, **Penno G**, Miccoli R, Gregori G, Navalesi R. Relation of glucose tolerance to complications of pregnancy in nondiabetic women. N Engl J Med. 1986; 315: 989-992. **IF: 53.298**

139. Miccoli R, Giampietro O, **Penno G**, Piaggesi A, Tognarelli M, Unterberger G, Navalesi R. A computerized information system for diabetes services. Life Support Syst. 1986; 4: 263-267.

140. Miccoli R, Marchetti P, Giampietro O, **Penno G**, Miccoli DF, Tallarigo L, Sampietro T, Navalesi R. Factitious hypoglycemia in an insulin-dependent woman in the eighth week of gestation. Gynecol Obstet Invest. 1986; 21: 52-56. **IF: 1.276**

B – Publications listed by PubMed due to participation to the EURODIAB IDDM Complications Study and the EURODIAB PCS (Prospective Complications Study)

1. Barutta F, Bruno G, Matullo G, Chaturvedi N, Grimaldi S, Schalkwijk C, Stehouwer CD, Fuller JH, Gruden G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study. Acta Diabetol. 2017; 54(2): 133-139. **IF:**

2. Balk SN, Schoenaker DA, Mishra GD, Toeller M, Chaturvedi N, Fuller JH, Soedamah-Muthu SS. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Association of diet and lifestyle with glycated haemoglobin in type 1 diabetes participants in the EURODIAB prospective complications study. Eur J Clin Nutr. 2016; 70: 229-36. **IF: 2.95**

3. Engelen L, Schalkwijk CG, Eussen SJ, Scheijen JL, Soedamah-Muthu SS, Chaturvedi N, Fuller JH, Stehouwer CD. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Low 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 levels are independently associated with macroalbuminuria, but not with retinopathy and macrovascular disease in type 1 diabetes: the EURODIAB prospective complications study. Cardiovasc Diabetol. 2015; 14: 67. **IF: 4.020**

4. Soedamah-Muthu SS, Vergouwe Y, Costacou T, Miller RG, Zgibor J, Chaturvedi N, Snell-Bergeon JK, Maahs DM, Rewers M, Forsblom C, Harjutsalo V, Groop PH, Fuller JH, Moons KG, Orchard TJ. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Predicting major outcomes in type 1 diabetes: a model development and validation study. Diabetologia. 2014; 57: 2304-2314. **IF: 6.880**

5. Engelen L, Soedamah-Muthu SS, Geleijnse JM, Toeller M, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Higher dietary salt intake is associated with microalbuminuria, but not with retinopathy in



individuals with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2014; 57: 2315-2323. **IF: 6.880**

6. Schoenaker DA, Simon D, Chaturvedi N, Fuller JH, Soedamah-Muthu SS; EURODIAB Prospective Complications Study Group. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB prospective complications study. J Clin Endocrinol Metab. 2014; 99: 800-807. **IF: 6.310**

7. Altorf-van der Kuil W, Engberink MF, Ijpma I, Verberne LD, Toeller M, Chaturvedi N, Fuller JH, Soedamah-Muthu SS. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Protein intake in relation to risk of hypertension and microalbuminuria in patients with type 1 diabetes**:** the EURODIAB Prospective Complications Study. J Hypertens. 2013; 31: 1151-1159. **IF: 4.222**

8. Soedamah-Muthu SS, Chaturvedi N, Fuller JH, Toeller M; EURODIAB Prospective Complications Study Group. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Do European people with type 1 diabetes consume a high atherogenic diet? 7-year follow-up of the EURODIAB Prospective Complications Study. Eur J Nutr. 2013; 52: 1701-1710. **IF: 3.840**

9. Tielemans SM, Soedamah-Muthu SS, De Neve M, Toeller M, Chaturvedi N, Fuller JH, Stamatakis E. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2013; 56: 82-91. **IF: 6.814**

10. van Bussel BC, Soedamah-Muthu SS, Henry RM, Schalkwijk CG, Ferreira I, Chaturvedi N, Toeller M, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Unhealthy dietary patterns associated with inflammation and endothelial dysfunction in type 1 diabetes: The EURODIAB study. Nutr Metab Cardiovasc Dis. 2013; 23: 758-764. **IF: 3.731**

11. Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, Pinach S, Manzo M, Loiacono M, Tricarico M, Mengozzi G, Witte DR, Fuller JH, Perin PC, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. NH2-Terminal Probrain Natriuretic Peptide Is Associated With Diabetes Complications in the EURODIAB Prospective Complications Study: The role of tumor necrosis factor-alpha. Diabetes Care. 2012; 35: 1931-1936. **IF: 8.087**

12. Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, Witte DR, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study. Diabetes Care. 2012; 35: 1598-1604. **IF: 8.087**

13. Schoenaker DA, Toeller M, Chaturvedi N, Fuller JH, Soedamah-Muthu SS; the EURODIAB Prospective Complications Study Group. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Dietary saturated fat and fibre and risk of cardiovascular disease and all-cause mortality among type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2012; 55: 2132-2141. **IF: 6.814**

14. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Eur J Endocrinol. 2012; 166: 325-332. **IF: 3.482**

15. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care. 2012; 35: 125-127. **IF: 8.087**

16. Charles M, Soedamah-Muthu SS, Tesfaye S, Fuller JH, Arezzo JC, Chaturvedi N, Witte DR;

EURODIAB Prospective Complications Study Investigators. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2010; 33: 2648-2653. **IF: 8.087**

17. Elliott J, Tesfaye S, Chaturvedi N, Gandhi RA, Stevens LK, Emery C, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care. 2009; 32: 1896-1900. **IF: 8.087**

18. Gruden G, Bruno G, Chaturvedi N, Burt D, Pinach S, Schalkwijk C, Stehouwer CD, Witte DR, Fuller JH, Cavallo-Perin P; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/ macrovascular complications in type 1 diabetes: the EURODIAB Study. J Intern Med. 2009; 266: 527-536. **IF: 5.483**

19. Burt D, Bruno G, Chaturvedi N, Schalkwijk C, Stehouwer CD, Witte DR, Fuller JH, Pinach S, Perin PC, Gruden G. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Anti-heat shock protein 27 antibody levels and diabetes complications in the EURODIAB study. Diabetes Care. 2009; 32: 1269-1271. **IF: 8.087**

20. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia. 2009; 52: 705-714. **IF: 6.814**

21. Beulens JW, Kruidhof JS, Grobbee DE, Chaturvedi N, Fuller JH, Soedamah-Muthu SS. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study. Diabetologia. 2008; 51: 1631-8. **IF: 6.814**

22. Gruden G, Bruno G, Chaturvedi N, Burt D, Schalkwijk C, Pinach S, Stehouwer CD, Witte DR, Fuller JH, Perin PC; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. Diabetes. 2008; 57: 1966-70. **IF: 8.286**

23. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008; 31: 1360-6. **IF: 8.087**

24. Soedamah-Muthu SS, Chaturvedi N, Pickup JC, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS). Diabetologia. 2008; 51: 493-501. **IF: 6.814**



25. Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, Fuller JH, Veglio M, Cavallo-Perin P; EURODIAB IDDM Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2007; 30: 2057-2063. **IF: 8.087**

26. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Arterial pulse pressure in relation to the duration of type 1 diabetes: a cross-sectional controlled study. Philips JC, Marchand M, Weekers L, Scheen AJ. Arch Mal Coeur Vaiss. 2006; 99: 683-686.

27. Ferriss JB, Webb D, Chaturvedi N, Fuller JH, Idzior-Walus B; EURODIAB Prospective Complications Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes. Diabet Med. 2006; 23: 557-564. **IF: 2.902**

28. Soedamah-Muthu SS, Chaturvedi N, Schalkwijk CG, Stehouwer CD, Ebeling P, Fuller JH; EURODIAB Prospective Complications Study group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients. J Diabetes Complications. 2006; 20: 188-195. **IF: 2.032**

29. Vérier-Mine O, Chaturvedi N, Webb D, Fuller JH. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Is pregnancy a risk factor for microvascular complications? The EURODIAB Prospective Complications Study. Diabet Med. 2005; 22: 1503-1509. **IF: 2.902**

30. Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH, Stehouwer CD; Eurodiab ProspectivE Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study. J Intern Med. 2005; 258: 450-459. **IF: 5.483**

31. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab. 2006; 91: 129-135. **IF: 5.967**

32. Giunti S, Bruno G, Veglio M, Gruden G, Webb DJ, Livingstone S, Chaturvedi N, Fuller JH, Perin PC; Eurodiab IDDM Complications Study. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Electrocardiographic left ventricular hypertrophy in type 1 diabetes: prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study. Diabetes Care. 2005; 28: 2255-2257. **IF: 8.087**

33. van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, Kofinis A, Rottiers R, Porta M, Chaturvedi N; EURODIAB prospective complications study. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care. 2005; 28: 1383-1389. **IF: 8.087**

34. Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CD; EURODIAB

Prospective Complications Study Group. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension. 2005; 46: 232-237. **IF: 6.207**

35. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB Prospective Complications Study. Diabetologia. 2005; 48: 370-378. **IF: 6.814**

36. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005; 352: 341-350. **IF: 53.298**

37. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005; 48: 164-171. **IF: 6.814**

38. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2004; 47: 1020-1028. **IF: 6.814**

39. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 2004; 27: 530-537. **IF: 8.087**

40. Schram MT, Chaturvedi N, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. J Hypertens. 2003; 21: 2035-2044. **IF: 4.021**

41. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2003; 26: 2165-2173. **IF: 8.087**

42. Chaturvedi N, Schalkwijk CG, Abrahamian H, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications **study**. Diabetes Care. 2002; 25: 2320-2327. **IF: 8.087**

43. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, Kerényi Z, Tamás G, Ward JD, Fuller JH; EURODIAB IDDM Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi

N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002; 19: 900-909. **IF: 2.902**

44. Soedamah-Muthu SS, Colhoun HM, Abrahamian H, Chan NN, Mangili R, Reboldi GP, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Trends in hypertension management in Type I diabetes across Europe, 1989/1990 - 1997/1999. Diabetologia. 2002; 45: 1362-1371. **IF: 6.814**

45. Veglio M, Giunti S, Stevens LK, Fuller JH, Perin PC; EURODIAB IDDM Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia: the EURODIAB IDDM Complications Study Group. Diabetes Care. 2002; 25: 702-707. **IF: 8.087**

46. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, Kerényi Z, Tamás G, Ward JD, Fuller JH. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Blood pressure response to standing in the diagnosis of autonomic neuropathy: the EURODIAB IDDM Complications Study. Arch Physiol Biochem. 2001; 109: 215-222. **IF: 0.841**

47. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, Fuller JH; EURODIAB Prospective Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia. 2001; 44: 2203-2209. **IF: 6.814**

48. Toeller M, Buyken AE, Heitkamp G, Cathelineau G, Ferriss B, Michel G; EURODIAB IDDM Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Nutrient intakes as predictors of body weight in European people with type 1 diabetes. Int J Obes Relat Metab Disord. 2001; 25: 1815-1822. **IF: 4.691**

49. Chaturvedi N, Fuller JH, Taskinen MR; EURODIAB PCS Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care. 2001; 24: 2071-2077. **IF: 8.087**

50. Idzior-Walus B, Mattock MB, Solnica B, Stevens L, Fuller JH; EURODIAB IDDM Complications Study Group. Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G. For the Center of Pisa, Italy: R. Navalesi, **G. Penno**, S. Bandinelli, R. Miccoli, M. Nannipieri. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med. 2001; 18: 786-96. **IF: 2.902**

51. Buyken AE, Toeller M, Heitkamp G, Karamanos B, Rottiers R, Muggeo M, Fuller JH; EURODIAB IDDM Complications Study Group. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Bandinelli. Glycemic index in the diet of European outpatients with type 1 diabetes: relations to glycated hemoglobin and serum lipids. Am J Clin Nutr. 2001; 73: 574-581. **IF: 6.7**

52. Crook MA, Pickup JC, Lumb PJ, Giorgino F, Webb DJ, Fuller JH; EURODIAB IDDM Complications Study Group. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Bandinelli. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study. Diabetes Care. 2001; 24: 316-22. **IF: 8.087**

53. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM; EURODIAB

Prospective Complications Study. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Bandinelli. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001; 24: 284-289. **IF: 8.087**

54. Soedamah-Muthu SS, Colhoun HM, Taskinen MR, Idzior-Walus B, Fuller JH; EURODIAB IDDM Complications Study Group. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Bandinelli. Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in Type I diabetic patients. Diabetologia. 2000; 43: 1353-1359. **IF: 6.814**

55. Buyken AE, Toeller M, Heitkamp G, Irsigler K, Holler C, Santeusanio F, Stehle P, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Bandinelli. Carbohydrate sources and glycaemic control in Type 1 diabetes mellitus. EURODIAB IDDM Complications Study Group. Diabet Med. 2000; 17: 351-359. **IF: 2.902**

56. Karamanos B, Porta M, Songini M, Metelko Z, Kerenyi Z, Tamas G, Rottiers R, Stevens LK, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Bandinelli. Different risk factors of microangiopathy in patients with type I diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia. 2000; 43: 348-355. **IF: 6.814**

57. Toeller M, Buyken AE, Heitkamp G, Berg G, Scherbaum WA. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Prevalence of chronic complications, metabolic control and nutritional intake in type 1 diabetes: comparison between different European regions. EURODIAB Complications Study group. Horm Metab Res. 1999; 31: 680-685. **IF: 2.188**

58. Toeller M, Buyken AE, Heitkamp G, Scherbaum WA, Krans HM, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Associations of fat and cholesterol intake with serum lipid levels and cardiovascular disease: the EURODIAB IDDM Complications Study. Exp Clin Endocrinol Diabetes. 1999; 107: 512-521. **IF: 1.693**

59. Collado-Mesa F, Colhoun HM, Stevens LK, Boavida J, Ferriss JB, Karamanos B, Kempler P, Michel G, Roglic G, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabet Med. 1999; 16: 41-48. **IF: 2.902**

60. Toeller M, Buyken AE, Heitkamp G, de Pergola G, Giorgino F, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi, A Bertolotto. Fiber intake, serum cholesterol levels, and cardiovascular disease in European individuals with type 1 diabetes. EURODIAB IDDM Complications Study Group. Diabetes Care. 1999; 22 Suppl 2: B21-28. **IF: 8.087**

61. Veglio M, Borra M, Stevens LK, Fuller JH, Perin PC. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complication Study Group. Diabetologia. 1999; 42: 68-75. **IF: 6.814**

62. Orchard TJ, Stevens LK, Forrest KY, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Cardiovascular disease in insulin dependent diabetes mellitus: similar rates but different risk factors in the US compared with Europe. Int J Epidemiol. 1998; 27: 976-983. **IF: 6.414**

63. Buyken AE, Toeller M, Heitkamp G, Vitelli F, Stehle P, Scherbaum WA, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi, A Bertolotto. Relation of fibre intake to HbA1c and the prevalence of severe ketoacidosis and severe hypoglycaemia. EURODIAB IDDM Complications Study Group. Diabetologia. 1998; 41: 882-890. **IF: 6.814**

64. Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Bandinelli. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med. 1998; 15: 418-426. **IF: 2.902**



65. Toeller M, Buyken A, Heitkamp G, Brämswig S, Mann J, Milne R, Gries FA, Keen H. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi, A Bertolotto. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia. 1997; 40: 1219-1226. **IF: 6.814**

66. Greaves M, Malia RG, Goodfellow K, Mattock M, Stevens LK, Stephenson JM, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study. Diabetologia. 1997; 40: 698-705. **IF: 6.814**

67. Sjølie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, Fuller J. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology. 1997; 104: 252-260. **IF: 5.454**

68. Toeller M, Buyken A, Heitkamp G, Milne R, Klischan A, Gries FA. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi, A Bertolotto. Repeatability of three-day dietary records in the EURODIAB IDDM Complications Study. Eur J Clin Nutr. 1997; 51: 74-80. **IF: 2.462**

69. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996; 39: 1377-1384. **IF: 6.814**

70. Stephenson JM, Kempler P, Perin PC, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study. Diabetologia. 1996; 39: 1372-1376. **IF: 6.814**

71. Toeller M, Klischan A, Heitkamp G, Schumacher W, Milne R, Buyken A, Karamanos B, Gries FA. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi, Dipartimento di Endocrinologia e Metabolismo, Pisa, Italy. Nutritional intake of 2868 IDDM patients from 30 centres in Europe. EURODIAB IDDM Complications Study Group. Diabetologia. 1996; 39 (8): 929-39. **IF: 6.814**

72. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care. 1996; 19: 689-697. **IF: 8.087**

73. Chaturvedi N, Stephenson JM, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications Study. Diabetes Care. 1996; 19: 423-430. **IF: 8.087**

74. Lloyd CE, Stephenson J, Fuller JH, Orchard TJ. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi, Dipartimento di Endocrinologia e Metabolismo, Pisa, Italy. A comparison of renal disease across two continents; the epidemiology of diabetes complications study and the EURODIAB IDDM Complications Study. Diabetes Care. 1996; 19 (3): 219-25. **IF: 8.087**

75. Glycosylated hemoglobin and the risk of microalbuminuria in insulin-dependent diabetes mellitus. EURODIAB IDDM Complications Study Group. Chaturvedi N, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. N Engl J Med. 1995; 333: 940-941. **IF: 53.298**

76. Chaturvedi N, Stephenson JM, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. The relationship between pregnancy and long-term maternal complications in the EURODIAB IDDM Complications Study. Diabet Med. 1995; 12: 494-499. **IF:**



2.902

77. Chaturvedi N, Stephenson JM, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care. 1995; 18: 785-792. **IF: 8.087**

78. Stephenson JM, Fuller JH, Viberti GC, Sjolie AK, Navalesi R. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study. Diabetologia. 1995; 38: 599-603. **IF: 6.814**

79. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjølie AK. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia. 1995; 38: 437-444. **IF: 6.814**

80. Stephenson JM, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, R Miccoli, M Nannipieri, S Manfredi. Microalbuminuria is not rare before 5 years of IDDM. EURODIAB IDDM Complications Study Group and the WHO Multinational Study of Vascular Disease in Diabetes Study Group. J Diabetes Complications. 1994; 8: 166-173. **IF: 2.032**

81. EURODIAB IDDM Complications Study Group. For the Center of Pisa, Italy: R Navalesi, G **Penno**, R Miccoli, M Nannipieri, S Manfredi. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994; 37: 278-285. **IF: 6.814**

C – Publications listed by PubMed due to participation to the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.

1. Schalkwijk CG, Chaturvedi N, Twaafhoven H, van Hinsbergh VW, Stehouwer CD; EUCLID Study Group. For the Center of Pisa, Italy: R Navalesi, **G Penno**, M Nannipieri, L Rizzo, R Miccoli. Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest. 2002; 32: 500-506. **IF : 2.736**

2. Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP; EUCLID Study Group. For the Center of Pisa, Italy: R Navalesi, **G Penno**, M Nannipieri, L Rizzo, R Miccoli. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med. 2001; 18: 288-294. **IF: 2.902**

3. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, M Nannipieri, L Rizzo, R Miccoli. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998; 351: 28-31. **IF: 38.28**

4. The EUCLID Study Group. For the Center of Pisa, Italy: R Navalesi, **G Penno**, M Nannipieri, L Rizzo, R Miccoli. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997; 349: 1787-1792. **IF: 38.28**

5. Webb DJ, Newman DJ, Chaturvedi N, Fuller JH. For the Center of Pisa, Italy: R Navalesi, **G Penno**, M Nannipieri, L Rizzo, R Miccoli. The use of the Micral-Test strip to identify the presence of microalbuminuria in people with insulin dependent diabetes mellitus (IDDM) participating in the EUCLID study. Diabetes Res Clin Pract. 1996; 31: 93-102. **IF: 2.754**

D – Publications listed by PubMed due to the participation to the Irbesartan Diabetic Nephropathy Trial (IDNT), the Collaborative Study Group.

1. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. Italy - V.E.

Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis. 2014; 64: 714-722. **IF: 5.756**

2. Riphagen IJ, Deetman PE, Bakker SJ, Navis G, Cooper ME, Lewis JB, de Zeeuw D, Lambers Heerspink HJ. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes. 2014; 63: 2845-2853. **IF: 8.474**

3. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis. 2014; 63: 244-250. **IF: 5.756**

4. Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D, Navis G, Lambers Heerspink HJ. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. Diabetes Care. 2013; 36: 1489-1494. **IF: 8.570**

5. Smink PA, Bakker SJ, Laverman GD, Berl T, Cooper ME, de Zeeuw D, Lambers Heerspink HJ. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. J Hypertens. 2012; 30: 1022-1028.

6. Evans M, Bain SC, Hogan S, Bilous RW; on behalf of the Collaborative Study Group participants. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrol Dial Transplant. 2012; 27: 2255-2263. **IF: 3.396**

7. Busch M, Franke S, Wolf G, Rohde RD, Stein G; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract. 2008; 108: c291-297. **IF: 2.038**

8. Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a



predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis. 2006; 48: 571-579. **IF: 5.434**

9. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005; 16: 3027-37. **IF: 9.663**

10. Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol. 2005; 16: 3397-402. **IF: 9.663**

11. Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int. 2005; 68: 773-8. **IF: 6.606**

12. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005; 16: 2170-9. **IF: 9.663**

13. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005; 45: 281-287. **IF: 5.434**

14. Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl. 2004; S99-101. Review. **IF: 6.606**

15. Aguilar D, Goldhaber SZ, Gans DJ, Levey AS, Porush JG, Lewis JB, Rouleau JL, Berl T, Lewis EJ, Pfeffer MA; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. Am J Cardiol. 2004; 94: 337-339. **IF: 3.368**

16. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis

JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl. 2004; S50-5. Review. **IF: 6.606**

17. Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ, Roze S, Annemans L, Simon TA, Chen RS, Lewis EJ; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther. 2003; 25: 2102-19. **IF: 2.321**

18. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; **Irbesartan Diabetic Nephropathy** Trial. Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003; 138: 542-549. **IF: 16.733**

19. Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy. Diabetes Care. 2002; 25: 2037-2041. **IF: 8.087**

20. Lewis EJ, Hunsicker LG, Rodby RA; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis. 2001; 38 (4 Suppl 1): S191-194. **IF: 5.434**

21. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Italy - V.E. Andreucci, S. Bandinelli, N. Bellotti, G.A. Cinotti, G. Crepaldi, A. Dal Canton, G. DeFerrari, E. Degli Esposti, C. Esposito, F. Locatelli, U. Malcangi, R. Mangili, G. Maschio, R. Navalesi, G. Norbiato, **G. Penno**, G. Piccoli, G. Pozza, F. Quarello, A. Ramello, F.P. Schena, A. Sessa, S. Stefoni, C. Zoccali. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851-60. **IF: 53.298**

E – Publications listed by PubMed due to the participation to the GENFIEV (GENetics, pathoPHYsiology and EVolution of type 2 diabetes)

1. Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo GM, Leonetti F, Del Prato S; on behalf of the **GENFIEV** Investigators. For the Center of Pisa: **Giuseppe Penno**, Annalisa Agostini. Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care. 2012; 35: 2607-2612. **IF: 8.087**

2. Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Alviggi L, Gnasso A, Consoli A, Cavalot F, Cavallo MG, Leonetti F, Giaccari A, Del Prato S; **GENFIEV**

Investigators. For the Center of Pisa: **Giuseppe Penno**, Annalisa Agostini. Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (**GENFIEV**) study. Nutr Metab Cardiovasc Dis. 2011; 21: 699-705. **IF: 3.731**

F – Publications listed by PubMed due to the participation to the ITALIAN MICROALBUMINURIA STUDY (IMSG)

1. Mangili R, Deferrari G, Di Mario U, Giampietro O, Navalesi R, Nosadini R, Rigamonti G, Crepaldi G. For the Italian Microalbuminuria Study Group (IMSG) area laboratories and co-ordinating clinic of Pisa: **Penno G**, Giampietro O, Navalesi R. Prevalence of hypertension and microalbuminuria in adult type 1 (insulin-dependent) diabetic patients without renal failure in Italy. I. Validation of screening techniques to detect microalbuminuria. Acta Diabetol 1992; 29: 156-166. **IF: 2.784**

2. Mangili R, Deferrari G, Di Mario U, Giampietro O, Navalesi R, Nosadini R, Rigamonti G, Spezia R, Crepaldi G, for the Italian Microalbuminuria Study Group. For the laboratory and co-ordinating clinic of Pisa: **G. Penno**, O. Giampietro, R. Navalesi. Arterial hypertension and microalbuminuria in IDDM: the Italian Microalbuminuria Study. Diabetologia. 1994; 37: 1015-24. **IF: 6.814**

G – Other Publications

1. Giampietro O, Cerri M, Lotti M, Miccoli R, Ferdeghini M, Marchetti P, **Penno G**, Tallarigo L, Sampietro T, Cai F, Navalesi R. Valutazione dell'asse ipotalamo ipofisi gonadi nel maschio diabetico. Rendiconti della Società Italiana di Medicina Interna. Atti dell'85° Congresso – Roma, 11-14 ottobre 1984; pp 421-423.

2. Tallarigo L, Giampietro O, **Penno G**, Moggi G, Miccoli R, Fioretti P, Navalesi R. Valutazione delle complicanze materno-fetali in rapporto al valore della glicemia alla seconda ora del carico orale di glucosio (OGTT) in gravide con normale tolleranza glucidica. Monduzzi Editore: LXIII Congresso Nazionale della Società Italiana di Ginecologia e Ostetricia. Milano 30 settembre-3 ottobre 1984; pp 1591-1596.

3. Giampietro O, Ferdeghini M, Miccoli R, Cerri M, Orlandi MC, **Penno G**, Masoni A, Muller EE, Navalesi R. Specific and non-specific growth-hormone (GH) response to hypophysiotropic neuropeptides in Type 1 diabetes mellitus: the role of the metabolic control. Pergamon Press: Protides of the Biological Fluids. 1986; 34: 209-212.

4. Miccoli R, Anichini R, Giampietro O, Di Palma L, Amato V, Di Cianni G, Tincani G, **Penno G**, Bertoli S, Cecere M, Navalesi R. Il piede diabetico: aspetti diagnostici e terapeutici. Atti II° Convegno "Incontri Diabetologici Pistoiesi" 22 marzo 1986. Bollettino Accademia Medica Pistoiese "F. Pacini" 1986; LV: 105-116.

5. Miccoli R, Odello G, Meucci G, Giampietro O, Marchetti P, **Penno G**, Navalesi R. Livelli dei lipidi plasmatici e severità della retinopatia diabetica valutata con metodo fluorangiografico. Bollettino di Oculistica 1987; 2 (suppl): 105-110.

6. Giampietro O, Miccoli R, Clerico A, Di Palma L, Cruschelli L, Palmieri L, **Penno G**, Gregori G, Anichini R, Bertoli S, Ronca G, Navalesi R. Markers urinary della nefropatia diabetica: aspetti metodologici e clinici. Parma-Diabete 1987 (7-8 maggio 1987), 1987; 99-104.

7. Giampietro O, Clerico L, Miccoli R, Di Palma L, Cruschelli L, Anichini R, Bertolotto A, **Penno G**, Gregori G, Giovannitti G, Navalesi R. Measurement of urinary albumin excretion rate in diabetic and normal subjects: more than an approach for more than a problem to solve. The Journal of Nuclear

Science and Allied Sciences 1887; 31: 80-82.

8. Giampietro O, Ferdeghini M, Miccoli R, Cerri M, Orlandi MC, Tognarelli M, **Penno G**, Gregori G, Navalesi R, Muller EE. Risposta del GH al GHRH, alla clonidina ed al TRH nel diabete mellito tipo 1. Atti XI Congresso Nazionale della Società Italiana di Diabetologia, Palermo, 4- 7 giugno 1986; Monduzzi Editore 1987; 361-369.

9. Giampietro O, Ferdeghini M, Miccoli R, Cerri M, Tognarelli M, **Penno G**, Di Palma L, Piaggesi A, Navalesi R. Funzione tiroidea nel diabete mellito non chetoacidosico. Atti XI Congresso Nazionale della Società Italiana di Diabetologia, Palermo, 4-7 giugno 1986; Monduzzi Editore 1987; 809-815.

10. Navalesi R, Miccoli R, **Penno G**, Giampietro O. Terapia del diabete mellito non insulino- dipendente. Aggiornamento del Medico 1987; 11: 596-611.

11. Tallarigo L, Giampietro O, **Penno G**, Miccoli R, Gregori G, Navalesi R. Relation of glucose tolerance to complications of pregnancy in nondiabetic women. 1987 The Year Book of Perinatal/neonatal Medicine. MH Klaus & AA Fanaroff Eds. 1987; 71-72.

12. Tallarigo L, Giampietro O, **Penno G**, Miccoli R, Gregori G, Navalesi R. Relation of glucose tolerance to complications of pregnancy in nondiabetic women. 1988 The Year Book of Obstetrics and Gynecology. DR Mishell, TH Kirschbaum, CP Morrow Eds. 1988; 81-83.

13. Navalesi R, **Penno G**, Gregori G, Mariani F, Bertoli S, Miccoli R, Giampietro O. Terapia con insulina umana da DNA ricombinante in soggetti diabetici in trattamento con insulina di origine animale: risultati del II Studio Multicentrico Italiano. II Workshop Lilly “Update sulla terapia del diabete”. Cortina, 18-20 dicembre 1987; pp 45-56.

14. **Penno G**, Giampietro O, Miccoli R, Gregori G, Bertoli S, Navalesi R. Il diabete gestazionale: nosologia e complicanze materno-fetali. Atti III° Convegno “Incontri Diabetologici Pistoiesi”. Bollettino Accademia Medica Pistoiese “F. Pacini” 1987; LVI: 7-23.

15. Giampietro O, **Penno G**, Miccoli R, Anichini R, Gregori G, Bertoli S, Navalesi R. La terapia della nefropatia diabetica con insufficienza renale. XII Congresso Nazionale della Società Italiana di Diabetologia. Venezia Lido 22-25 maggio 1988. CIC Ediz. Internazionali 1988: pp 869-877.

16. Giampietro O, Miccoli R, Cruschelli L, Bertolotto A, Giovannitti G, **Penno G**, Navalesi R. Serum fructosamine in diabetes mellitus by a colorimetric test: methodological aspects and clinical results. Progressi in Medicina di Laboratorio 2: 21-27, 1988.

17. Giampietro O, Miccoli R, Clerico A, Di Palma L, Cruschelli L, **Penno G**, Gregori G, Anichini R, Bertoli S, Iozzi L, Navalesi R. La microalbuminuria nel diabete mellito: epidemiologia e clinica. Atti del VI Congresso Nazionale Associazione Medici Diabetologi (AMD). Grado, 9-11 aprile 1987. Monduzzi Editore, Bologna, 1988: pp 355-361.

18. Giampietro O, Clerico A, Gregori G, Bertoli S, Lucchetti A, Cruschelli L, **Penno G**, Navalesi R. Aumentata escrezione urinaria di attività immunologica digitalico-simile (DLIS) nel diabete mellito insulino-dipendente. The Ligand Quarterly 1988; 7: 55-57.

19. **Penno G**, Giampietro O, Navalesi R. Epidemiologia dell’ipertensione arteriosa nel diabete mellito. Atti del Convegno “Diabete ed Ipertensione”. Bologna, 28-29 ottobre 1988; pp 49-57.

20. **N**avalesi R, **Penno G**, Giampietro O. Insulinoterapia: farmacocinetica e impiego clinico. Il Diabete 1989; 1: 15-35.

21. Giampietro O, **Penno G**, Palmieri L, Bertoli S, Gregori G, Lucchetti A, Cruschelli L, Castro- Lopez E, Caricato F, Miccoli R, Cecere M, Ronca G, Navalesi R. Enzimuria e tubulopatia diabetica: più di un semplice sospetto. Atti del VII Congresso Nazionale Associazione Medici Diabetoloci (AM). Rimini 31 maggio-3 giugno 1989: pp 335-338.

22. Anichini R, Bertoli S, Amato V, Giampietro O, Cecere M, **Penno G**, Gregori G, Marchetti N, Navalesi R. Il "piede diabetico": itinerario diagnostico ed approcci terapeutici. Diabete Oggi. Atti delle Quarte Giornate Diabetologiche dell'Università Cattolica del Sacro Cuore. Roma, 26-27 febbraio 1988; pp 203-206.

23. Miccoli R, Cai F, Bertolotto A, Giampietro O, **Penno G**, Navalesi R. Aspetti epidemiologici dell'obesità nel diabete di tipo 1 (insulino-dipendente) e di tipo 2 (non insulino-dipendente). In: Obesità 1988. Fisiologia, Clinica e Terapia. Melchionda N, Enzi G, Bosello D, Eds. Casa Editrice Luigi Parma, Bologna, 1989; pp 505-514.

24. Miccoli R, Bertolotto A, Giovannitti G, Viegi G, Vellutini M, **Penno G**, Giampietro O, Navalesi R. Circulating lipids and apolipoproteins after short-term assumption of nicotine chewing- gum. Clinica e Terapia Cardiovascolare. 1989; VIII: 153-156.

25. Miccoli R, Bertolotto A, Giovannitti G, Tedesco I, **Penno G**, Giampietro O, Navalesi R. Cholesterol and triglyceride evaluation by desktop system: analytical aspects, clinical advantages. Clinica e Terapia Cardiovascolare. 1989; VIII: 237-240.

26. Miccoli R, Orlandi MC, Fruzzetti F, Melis GB, Giampietro O, Ricci C, Bertolotto A, Masoni A, **Penno G**, Fioretti P, Navalesi R. Effetti dei contraccettivi orali a basse dosi sul metabolismo glicidico. Minerva Endocrinologica. 1989: 41: 441-444.

27. Giampietro O, **Penno G**, Palmieri L, Bertoli S, Gregori G, Cruschelli L, Ronca G, Navalesi R. Tubular enzymuria in insulin-dependent (IDDM) and non insulin-dependent (NIDDM) diabetic patients. In: Diabetes, Obesity and Hyperlipidemias-IV. Proceedings of the %th European Symposium on Metabolism, Padova, 15-17 May, 1989. Crepaldi G, Tiengo A, Enzi G, Eds. Excerpta Medica 1990: pp 447-450.

28. **Penno G**, Gregori G, Bertoli S, Cruschelli L, Anichini R, Lucchetti A, Palmieri L, Del Chicca MG, Clerico A, Nannipieri M, Navalesi R, Giampietro O. Diagnosi precoce della nefropatia diabetica: risultati clinico-epidemiologici, aspetti fisiopatologici, ipotesi di lavoro. Parma Diabete '90, Parma 20-21 aprile 1990, pp 125-132.

29. **V**olpe L, Cionini R, Dreini L, **Penno G**, Barletta D, Bagnolesi A, Catarsi L, Vassallo G, Luisi M, Franchi F. Significato delle variazioni della prolattina (PRL) indotte dalla somministrazione acuta di nalozone e protratta di naltrexone nell'amenorrea ipotalamica funzionale (AI). Aggiornamenti in Scienze Ginecologiche ed Ostetriche. atti del IV Congresso Nazionale, Isola d'Elba, 3-10 giugno 1990, pp 603-606.

30. Giampietro O, **Penno G**, Gregori G, Palmieri L, Bertoli S, Anichini R, Cruschelli L, Nannipieri M, Cecere M, Ronca G, Navalesi R, Miccoli R. Increased Enzymuria in Diabetes Mellitus: a signal of tubular involvement in diabetic nephropathy. Frontiers in Diabetes 1990: 10: 173- 176.

31. Navalesi R, Anichini R, Bertoli S, Amato V, Miccoli R, Cecere M, **Penno G**, Giampietro O. Il piede diabetico: diagnosi e terapia. In: Il trattamento delle trombosi arteriose. Recenti Progressi. Sacripanti A, Grassi B, Eds. ETS Editrice, 1990: pp 331-347.

32. **Penno G**, Gregori G, Bertoli S, Nannipieri M, Rizzo L, Lucchetti A, Cecere M, Navalesi R, Giampietro O. Ipertensione arteriosa e diabete mellito: differenze tra diabete insulino- dipendente e diabete non insulino-dipendente. Atti IV° Convegno "Incontri Diabetologici Pistoiesi" 22 marzo 1986. Bollettino Accademia Medica Pistoiese "F. Pacini" 1989; LIX: 29- 40.

33. **Penno G**, Cruschelli L, Gregori G, Bertoli S, Lucchetti A, Giordani R, Nannipieri M, Rizzo L, Clerico A, Navalesi R, Giampietro O. La microalbuminuria nel diabete mellito: quale campione utilizzare e con quale metodo dosare. Atti IV° Convegno "Incontri Diabetologici Pistoiesi" 22 marzo 1986. Bollettino Accademia Medica Pistoiese "F. Pacini" 1989; LIX: 41- 67.

34. Giampietro O, **Penno G**, Bertoli S, Gregori G, Cruschelli L, Anichini R, Lucchetti L, Nannipieri M, Fazzi L, Rossi M, Dolci MA, Meniconi RM, Ferrari E, Trifirò R, Falloppa C, Fiaschi L, Navalesi R. Prevalenza della nefropatia diabetica in Italia: Studio multicentrico della Toscana Occidentale. Nefrologia, Dialisi, Trapianto. Wichtig Editore, Milano 1990; pp 193-196.

35. **Penno G**, Bertoli S, Gregori G, Cruschelli L, Anichini R, Lucchetti L, Nannipieri M, Fazzi L, Rossi M, Dolci MA, Meniconi RM, Ferrari E, Trifirò R, Falloppa C, Fiaschi L, Navalesi R, Giampietro O. Studio multicentrico sulla prevalenza della nefropatia diabetica nella Toscana Occidentale. Il Diabete 1991; 3 (suppl 2) 631-634.

36. **Penno G**, Bertoli S, Cecere M, Cruschelli L, Nannipieri M, Rizzo L, Rapuano A, Navalesi R, Giampietro O. La concentrazione plasmatica del C-peptide a digiuno e dopo stimolo con glucagone quali indici di funzione beta-cellulare residua. Obiettivo Diabete 1991; 1: 17-26.

37. Giampietro O, **Penno G**, Anichini R, Di Mario U, Navalesi R. L'infusione di dopamina modifica la permeabilità della membrana glomerulare nel diabete mellito tipo 1. 32° Congresso Nazionale della Società Italiana di Nefrologia. Bologna 29 maggio-1 giugno 1991. Bonomini V, Stefoni S, Vangelista A, Eds. Monduzzi Editore, 1991: pp 165-170.

38. **Penno G**, Clerico A, Cruschelli L, Lucchetti A, Nannipieri M, Rizzo L, Cecere M, Giampietro O. Dosaggio dell'albumina urinaria: metodi immunologici a confronto 32° Congresso Nazionale della Società Italiana di Nefrologia. Bologna 29 maggio-1 giugno 1991. Bonomini V, Stefoni S, Vangelista A, Eds. Monduzzi Editore, 1991: pp 223-228.

39. Giampietro O, Clerico A, **Penno G**, Navalesi R. La microalbuminuria: perchè valutarla, con quale metodo e su quale campione dosarla. Il Diabete 1991; 3 (3): 233-241.

40. Navalesi R, Penno G, Giampietro O. Controllo metabolico e progressione della nefropatia diabetica. Il Diabete 1991; 3 (3): 132-144.

41. Navalesi R, Giampietro O, **Penno G**. Inibitori dell'aldoso reduttasi e nefropatia diabetica. Il Diabete 1991; 3 (suppl 3): 33-48.

42. Volpe L, Cionini R, **Penno G**, Pruneti C, Catarsi AL, Barletta D, Franchi F. Valutazione della funzione ipotalamo-ipofisi-gonadi in pazienti con amenorrea ipotalamica trattate con naltrexone. Aggiornamenti in Scienze Ginecologiche ed Ostetriche. Isola d'Elba, 9-16 giugno 1991. P Fioretti Ed. CIC Edizioni Internazionali. 1991, pp1215-1218.

43. Giampietro O, **Penno G**, Gregori G, Bertoli S, Cruschelli L, Lucchetti A, Nannipieri M, Rizzo L, Navalesi R. Epidemiology of Diabetic Nephropathy in Europe. In: D Andreani, JL Gueriguan, Striker GE, Conti FG, Eds. Diabetic Complications – Epidemiology and pathogenetic mechanisms. Serono Symposia Publications from Raven Press. 1991; Vol 69: pp 97-106.

44. Giampietro O, Clerico A, **Penno G**. L'albuminuria identifica i pazienti a rischio per nefropatia diabetica. Medicina Generale 1992; IX: 29-33.

45. Clerico A, **Penno G**, Giampietro O. Importanza, significato clinico e considerazioni metodologiche dell'albuminuria nel paziente diabetico. Minerva Endocrinologica 1992; 16: 1- 6.

46. **Penno G**, Giampietro O, Nannipieri M, Rizzo L, Rapuano A, Miccoli R, Bertolotto A, Cecere M, Lucchetti A, Navalesi R. Increased urinary albumin excretion aggregates with atherosclerotic risk

factors in type 2 (non-insulin-dependent) diabetes mellitus. Acta Diabetol 1992; 29: 250-257.

47. Italian Microalbuminuria Study Group, a cura di **Penno G**, Clerico A, Cruschelli L, Cecere M, Rizzo L, Nannipieri M, Rapuano A, Crepaldi G, Rigamonti G, Giampietro O, Navalesi R. Controllo di qualità interlaboratori per il dosaggio radioimmunologico dell'albumina urinaria: l'esperienza dell'Italian Microalbuminuria Study Group. Il Diabete 1992; 4 (suppl 1): 416-419.

48. Nannipieri M, **Penno G**, Rizzo L, Cecere M, Cruschelli L, Lucchetti A, Rapuano A, Giampietro O, Navalesi R. Aumentata escrezione urinaria di albumina e fattori di rischio cardiovascolare nel diabete tipo 2. Il Diabete 1992; 4 (suppl 1): 412-415.

49. Giampietro O, **Penno G**, Nannipieri M, Rizzo L, Cecere M, Rapuano A, Cruschelli L, Lucchetti A, Navalesi R. Diabetic nephropathy in IDDM and NIDDM: prevalence and different linkage with arterial hypertension and retinal involvement. Findings from the West-Tuscany Multicenter Study. Belfiore F, Bergman RN, Molinatti GM Eds: Current Topics in Diabetes Research. Front Diabetes. Basel, Karger 1993; 12: 234-239.

50. Navalesi R, Bertolotto A, Galantini G, **Penno G**, Miccoli R. Lipid and lipoprotein abnormalities and diabetic complications. In G Crepaldi, A Tiengo, E Manzato Eds. Diabetes, obesity and hyperlipidemia: V The plurimetabolic syndrome. Elsevier Science Publishers. pp 215-225.

51. Giampietro O, **Penno G**. Possibilità di ritardare la progressione della nefropatia diabetica. Il Diabete. 1993; 5 (2): 157-160.

52. Navalesi R, **Penno G**. La nefropatia diabetica: storia naturale, patogenesi, diagnosi e principi di terapia. IV Convegno Post-specialistico di Aggiornamento in Endocrinologia Clinica. Roma, 20-23 ottobre 1993; pp 241-254.

53. Rapuano A, Giampietro O, **Penno G**, Nannipieri M, Rizzo L, Cecere M, Cruschelli L, Miccoli R, Navalesi R. Nefropatia, retinopatia e ipertensione arteriosa: associazioni diverse nel diabete insulino-dipendente (IDDM) e non insulino-dipendente (NIDDM). A Antonelli Ed. Rene ed Ipertensione arteriosa. Editoriale BIOS 1994; pp 303-314.

54. Nannipieri M, Rizzo L, Rapuano A, Pilo A, Penno G, Navalesi R. Transcapillary escape rate dell'albumina e microalbuminuria nel diabete mellito tipo 2 (non insulino-dipendente). A Antonelli Ed. Rene ed Ipertensione arteriosa. Editoriale BIOS 1994; pp 315-336.

55. Rizzo L, **Penno G**, Miccoli R, Nannipieri M, Rapuano A, Bertolotto A, Manfredi S, Galantini G, Castro-Lopez E, Piaggesi A, Stephenson J, Fuller JH, Navalesi R. Prevalenza della nefropatia diabetica in Europa ed interazione con i principali fattori di rischio: l'EURODIAB IDDM Complications Study. A Antonelli Ed. Rene ed Ipertensione arteriosa. Editoriale BIOS 1994; pp 273-302.

56. Navalesi R, Bertolotto A, Galantini G, **Penno G**, Miccoli R, Manfredi S. Anomalie dei lipidi e delle lipoproteine e complicanze microvascolari nel diabete mellito. IX Giornate Diabetologiche Sarde, Quartu S. Elena 9-12 ottobre 1994, pp 95-104.

57. Rizzo L, **Penno G**, Navalesi R. La nefropatia nel diabete mellito tipo 2. Focus on Diabetic Complications. 1994; 4: 4-12.

58. **Penno G,** Rizzo L, Nannipieri M, Rapuano A, Navalesi R. La nefropatia diabetica: dalla patogenesi alla terapia. Il Diabete 1994; 6 (4): 197-222.

59. **Penno G**, Miccoli R, Nannipieri M, Rizzo L, Rapuano A, Bertolotto A, Manfredi S, Galantini G, Castro-Lopez E, Piaggesi A, Stephenson J, Fuller JH, Navalesi R e l'EURODIAB IDDM Complications Study Group. EURODIAB IDDM Complications Study: prevalenza della nefropatia diabetica ed interazione con i principali fattori di rischio. Atti VI° Convegno "Incontri Diabetologici Pistoiesi" 1994-95. Bollettino

Accademia Medica Pistoiese “F. Pacini” 1994-1995; LXI: 31-62.

60. Navalesi R, **Penno G**, Miccoli R, Piaggesi A, Nannipieri M, Manfredi S, Bertolotto A, Rizzo L, Rapuano A, Stephenson J, Fuller JH e l’EURODIAB IDDM Complications Study Group. Epidemiologia delle complicanze del diabete mellito insulino-dipendente in Europa: anticipazioni dallo Studio EURODIAB. Atti VI° Convegno “Incontri Diabetologici Pistoiesi” 1994-95. Bollettino Accademia Medica Pistoiese “F. Pacini” 1994-1995; LXI: 63-77.

61. **Penno G**, Rizzo L, Nannipieri M, Rapuano A, Navalesi R. La nefropatia diabetica: epidemiologia, storia naturale, patogenesi e terapia. Atti VI° Convegno “Incontri Diabetologici Pistoiesi” 1994-95. Bollettino Accademia Medica Pistoiese “F. Pacini” 1994-1995; LXI: 79- 126.

62. Rizzo L, **Penno G**, Rapuano A, Nannipieri M, Cecchetti P, Bandinelli S, Bertacca A, Pucci L, Bertolotto A, Navalesi R. Inibitore dell’attivatore del plasminogeno (PAI-1), attivatore tessutale del plasminogeno (t-PA) ed albuminuria nel diabete mellito tipo 2. X° Congresso Nazionale della Associazione Medici Diabetologi (AMD), Cosenza, 4-7 ottobre 1995, Atti; pp 465-473.

63. Nannipieri M, **Penno G**, Rizzo L, Rapuano A, Bandinelli S, Pucci L, Bertacca A, Miccoli R, Navalesi R. Transcapillary escape rate dell’albumina, microalbuminuria ed ipertensione arteriosa nel diabete mellito non insulino-dipendente. X° Congresso Nazionale della Associazione Medici Diabetologi (AMD), Cosenza, 4-7 ottobre 1995, Atti; pp 511-519.

64. Bertolotto A, Miccoli R, **Penno G**, Rizzo L, Nannipieri M, Rapuano A, Caricato F, Cannistraro D, Bandinelli S, Navalesi R. Anomalie della composizione lipoproteica ed escrezione urinaria di albumina in pazienti diabetici non insulino-dipendenti (NIDDM). X° Congresso Nazionale della Associazione Medici Diabetologi (AMD), Cosenza, 4-7 ottobre 1995, Atti; pp 859-860.

65. Rapuano A, **Penno G**, Rizzo L, Nannipieri M, Bandinelli S, Pucci L, Bertacca A, Caricato F, Navalesi R. Monitoraggio della pressione arteriosa (AMBP) in diabetici tipo 1 (IDDM) con normale escrezione urinaria di albumina. X° Congresso Nazionale della Associazione Medici Diabetologi (AMD), Cosenza, 4-7 ottobre 1995, Atti; pp 503-509.

66. **Penno G**, Nannipieri M, Bandinelli S, Rizzo L, Pucci L, Marsocci A, Navalesi R. La nefropatia diabetica e la gravidanza. In “La donna diabetica e la gravidanza: problematiche attuali” Pisa, 14-15 novembre 1996. Pacini Editore, 1996, pp 57-66.

67. **Penno G**, Nannipieri M, Rizzo L, Rapuano A, Bandinelli S, Bertacca A, Pucci L, Navalesi R. La nefropatia diabetica: terapia con farmaci antiipertensivi. V Corso Post-specialistico di aggiornamento in Endocrinologia Clinica. Abano/Montegrotto Terme (PD), 13-16 marzo 1996; pp 140-147.

68. Navalesi R, Nannipieri M, Bandinelli S, Pucci L, **Penno G**. Diabete, ipertensione e rischio cardiovascolare. Il Diabete 1997; 9 (suppl 2): 19-21.

69. Navalesi R, Bandinelli S, Nannipieri M, Pucci L, Rizzo L, Marsocci A, Pilo M, Penno G. Ipertensione arteriosa e nefropatia diabetica. In: A Antonelli Ed. Ipertensione arteriosa. Lucca 29 novembre 1997; pp 39-78.

70. Nannipieri M, **Penno G**, Bertacca A, Pucci L, Bandinelli s, Rizzo L, Navalesi R. Polimorfismo C/T nel gene del Peptide Natriuretico Atriale in soggetti con diabete mellito tipo 1. V Convegno Nazionale. Parma Diabete 1997. Atti; 1997; pp 56-59.

71. Caricato F, Bertolotto A, Benzi L, Mammini C, Aragona M, **Penno G**, Navalesi R. Valutazione del sistema Tosoh HLC-723 Ghb V A1c 2.2 Eurogenetics per la determinazione dell’emoglobina glicata. Biochimica Clinica 1998; 22 (7-8): 425-430.

72. Pucci L, Bandinelli S, **Penno G**, Nannipieri M, Rizzo L, Navalesi R. Iohexol plasma clearance in

determining glomerular filtration rate in diabetic patients. Renal Failure 1998; 20 (2): 277- 284.

73. Bandinelli S, Dell'Omo G, Nannipieri M, Pucci L, Pedrinelli R, Navalesi R, **Penno G**. Insulin Resistance and endothelial dysfunction in hypertensive and atherosclerotic non diabetic subjects. 20th European Conference on Microcirculation. Paris, 30 august - 2 september, 1998. Monduzzi Editore, Bologna, 1998; pp 69-74.

74. Pucci L, Nannipieri M, Bandinelli S, Pilo M, Mangili R, Navalesi R, **Penno G**. PlA1/PlA2 polymorhism of platelet glycoprotein IIIA receptor and microangiopathy in type 1 diabetes mellitus. 20th European Conference on Microcirculation. Paris, 30 august - 2 september, 1998. Monduzzi Editore, Bologna, 1998; pp 43-48.

75. Bandinelli S, Dell'Omo G, **Penno G**, Pucci L, Nannipieri M, Mariani M, Navalesi R, Pedrinelli R. Short-term aggressive LDL-lowering in atherosclerotic patients: effects on endothelial- mediated vasodilation and capillary permeability. 20th European Conference on Microcirculation. Paris, 30 august - 2 september, 1998. Monduzzi Editore, Bologna, 1998; pp 313-318.

76. Nannipieri M, Pucci L, Bandinelli S, Rizzo L, Navalesi R, **Penno G**. C708T polymorphism at the human atrial natriuretic peptide (hANP) gene and endothelial dysfunction in type 1 diabetic patients. 20th European Conference on Microcirculation. Paris, 30 august - 2 september, 1998. Monduzzi Editore, Bologna, 1998; pp 63-67.

77. Pucci L, Bandinelli S, **Penno G**, Pilo M, Navalesi R, Bertolotto A. Effetti dell'atirvastatina sui livelli plasmatici di omocisteina in soggetti con ipercolesterolemia familiare. In: Buoncristiani U e Timio M Eds. Nefrologia, Dialisi & Trapianto. 40° Congresso della Società Italiana di Nefrologia. Editoriale Bios 1999; pp 71-74.

78. Pucci L, Bandinelli S, Pilo M, Zerbini G, Mangili R, **Penno G**, Navalesi R. Polimorfismi del gene della glicoproteina piastrinica Iib/IIIa e complicanze renali e retiniche nel diabete tipo 1. In: Buoncristiani U e Timio M Eds. Nefrologia, Dialisi & Trapianto. 40° Congresso della Società Italiana di Nefrologia. Editoriale Bios 1999; pp 179-184.

79. Pucci L, Bandinelli S, Pilo M, Marsocci A, Navalesi R, **Penno G**. Clearance plasmatica dello iohexolo quale misura del GFR nel paziente con diabete mellito: valutazione di un approccio semplificato. In: Buoncristiani U e Timio M Eds. Nefrologia, Dialisi & Trapianto. 40° Congresso della Società Italiana di Nefrologia. Editoriale Bios 1999; pp 185-190.

80. Pucci L, Pilo M, Bandinelli S, Navalesi R, **Penno G**. Polimorfismo 4G/5G del promoter del gene del PAI-1 e complicanze renali e retiniche nel diabete tipo 1. In: Buoncristiani U e Timio M Eds. Nefrologia, Dialisi & Trapianto. 40° Congresso della Società Italiana di Nefrologia. Editoriale Bios 1999; pp 191-196.

81. Bandinelli S, Dell'Omo G, Pucci L, Cecchetti P, Mariani M, Navalesi R, Pedrinelli R, **Penno G**. Ipertensione essenziale e aterosclerosi: associazione tra disfunzione endoteliale e sensibilità insulinica. In: Buoncristiani U e Timio M Eds. Nefrologia, Dialisi & Trapianto. 40° Congresso della Società Italiana di Nefrologia. Editoriale Bios 1999; pp 209-213.

82. Bandinelli S, Dell'Omo G, Pucci L, Cecchetti P, Mariani M, Navalesi R, Pedrinelli R, **Penno G**. Effetti della simvastatina sulla permeabilità del microcircolo indipendenti dal profilo lipidico e dalla pressione arteriosa. In: Buoncristiani U e Timio M Eds. Nefrologia, Dialisi & Trapianto. 40° Congresso della Società Italiana di Nefrologia. Editoriale Bios 1999; pp 203-207.

83. Bandinelli S, Bertolotto A, Pucci L, Navalesi R, **Penno G**. Effetto dell'atorvastatina sulla pressione arteriosa: dati preliminari. In: Buoncristiani U e Timio M Eds. Nefrologia, Dialisi & Trapianto. 40° Congresso della Società Italiana di Nefrologia. Editoriale Bios 1999; pp 215- 218.

84. **Penno G**, Bandinelli S, Pucci L, Lucchesi D, Navalesi R. Trattamento intensivo dell'ipertensione arteriosa nel paziente diabetico: evidenze epidemiologiche e cliniche. In: A Antonelli Ed. Ipertensione arteriosa. Editoriale Bios 1999; pp 31-52.

85. Marsocci A, Pucci L, Bandinelli S, Pilo M, Navalesi R, **Penno G**. Clearance plasmatica dello iohexolo per la misurazione del GFR nel paziente con diabete mellito: valutazione di un approccio semplificato. XII Congresso della Associazione Medici Diabetologi. Cagliari 26-29 maggio 1999; Atti; pp 247-252.

86. Bandinelli S, Dell'Omo G, Pucci L, Cecchetti P, Mariani M, Navalesi R, Pedrinelli R, **Penno G**. Disfunzione endoteliale e sensibilità insulinica nell'ipertensione essenziale e nell'aterosclerosi. XII Congresso della Associazione Medici Diabetologi. Cagliari 26-29 maggio 1999; Atti; pp 321-326.

87. Pucci L, Bandinelli S, Pilo M, Navalesi R, **Penno G**. Polimorfismo 4G/5G del promoter del gene del PAI-1 e rischio di complicanze microangiopatiche nel diabete tipo 1. Congresso della Associazione Medici Diabetologi. Cagliari 26-29 maggio 1999; Atti; pp 573-577.

88. Pucci L, Pilo M, Bandinelli S, Zerbini G, Mangili R, Navalesi R, **Penno G**. Glicoproteina piastrinica Iib/IIIa: polimorfismi genici e complicanze microvascolari nel diabete tipo 1. Congresso della Associazione Medici Diabetologi. Cagliari 26-29 maggio 1999; Atti; pp 579- 584.

89. Rizzo L, Bandinelli S, Bertolotto A, Pucci L, Navalesi R, **Penno G**. Effetto delle statine sulla pressione arteriosa: dati preliminary con atorvastatina. Congresso della Associazione Medici Diabetologi. Cagliari 26-29 maggio 1999; Atti; pp 771-773.

90. Bertolotto A, Pucci L, Bandinelli S, Caricato F, Giovannitti G, Pilo M, Navalesi R, **Penno G**. Ipercolesterolemia familiare: effetti dell'atorvastatina sui livelli plasmatici di omocisteina. Congresso della Associazione Medici Diabetologi. Cagliari 26-29 maggio 1999; Atti; pp 827- 830.

91. Bandinelli S, Dell'Omo G, Pucci L, Giovannitti G, Caricato F, Mariani M, Pedrinelli R, Navalesi R, **Penno G**. La simvastatina migliora la permeabilità del microcircolo indipendentemente dagli effetti sul profilo lipidico e sulla pressione arteriosa. Congresso della Associazione Medici Diabetologi. Cagliari 26-29 maggio 1999; Atti; pp 831-835.

92. Cavallo Perin P, De Cosmo S, Fioretto P, Mangili R, **Penno G**, Pugliese G, Trevisan R. Nefropatia diabetica: screening, diagnosi, terapia. Il Diabete 2000; 12 (4): 299-303.

93. **Penno G**, Bandinelli S, Pucci L, Lucchesi D, Miccoli R, Del Prato S. Epidemiologia della nefropatia nel diabete mellito. In: Di Paolo N e Buoncristiani U Eds. Tecniche Nefrologiche e Dialitiche. Editoriale BIOS 2001; 247-276.

94. **Penno G**, Bandinelli S, Pucci L, Lucchesi D, Miccoli R, Del Prato S. Inibitori della HMG-CoA reduttasi (statine) e funzione endoteliale. Atti del III Meeting Regionale Toscano della SISA. Montecatini Terme, 20 aprile 2001, pp 19-51.

95. **Penno G**, Bandinelli S, Pucci L, Lucchesi D, Del Prato S. La proteinuria nel diabete: epidemiologia, prpgressione verso l'insufficienza renale, comorbidità e potenzialità del trattamento antipertensivo. In: A Antonelli Ed. Le Proteinurie. Studio Del Carlo Editore. Lucca 19-20 gennaio, 2001; pp 22-53.

96. **Penno G.** Obiettivi del trattamento del diabete mellito. In: Il Diabete a portata di mano. S Del Prato, L Benzi, Eds. Primula Multimedia Editore 2002; pp 4-16.

97. **P**enno G, Pucci L, Lucchesi D, Pellegrini G, Miccoli R, Del Prato S. Diagnostica di laboratorio: esami su urine. Gli esami per il diabete. Rivista di Medicina di Laboratorio 2002; 3 (1): 44-53.

98. Miccoli R, **Penno G**, Del Prato S. Significato clinico della sindrome metabolica e rischio cardiovascolare. La Cardiologia nella Pratica Clinica 2003; 10 (2): 101-120.

99. **Penno G**, Pucci L, Miccoli R. L'infiammazione: un evento centrale nella patogenesi dell'aterosclerosi. In: Rischio Cardiovascolare Globale. Un approccio Multidisciplinare. Momento Medico Editore, 2003; 69-83.

100. **Penno G,** Pucci L, Miccoli R. Screening e follow-up della nefropatia diabetica. Il Diabete 312003; 15 (1): 3-13.

101. **Penno G**, Baldassari E, Pucci L. Quale trattamento antipertensivo nel paziente diabetico: ACE-inibitori e antagonisti recettoriali a confronto: Antagonisti Recettoriali. Il Diabete 2004; 16 (2): 164-174.

102. Reboldi GP, Muggeo M, Santeusanio F, Giogino F, Porta M, **Penno G**, Ghirlanda G. Dataset italiano dello Studio EURODIAB. Il Diabete 2004; 16 (4): 358-367.

103. Bianchi C, Miccoli R, **Penno G**, Benzi L, Del Prato S. Insulina: un ormone aterogeno? Il Diabete 2004; 15 (1): 60-68.

104. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Crepaldi G. Dial Study Group, Pisa: Benzi L, **Penno G**. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria. DIAL Study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab. 2004; 17 (5): 259-266.

105. Miccoli R, **Penno G**, Del Prato S. Screening del diabete di tipo 2 e possibilità di prevenzione. Medico e Paziente 2004; XXX (8): 12-17.

106. Del Prato S, Miccoli R, **Penno G**. Prevenire il diabete per prevenire la malattia cardiovascolare? In: La cardiopatia diabetica. Dalla fisiopatologia alla clinica. 2004; pp 11-30.

107. **Penno G**, Pucci L, Baldassari E, Miccoli R, Del Prato S. L'iperteso con syndrome metabolica. Il Cardiologo 2004; 4 (2): 40-47.

108. **Penno G**, Pucci L. Effetti pleiotropici delle statine. Pro e Contro. Scenari in Medicina Cardiovascolare 2004; 1 (1), pp 22-23.

109. **Penno G**, Pucci L, Miccoli R. Spot. Scenari in Medicina Cardiovascolare 2004; 1 (3), pp 24- 28.

110. Bianchi C, Agostini A, **Penno G**, Miccoli R, Del Prato S. Prevenire il diabete è oggi possible. Metabolismo Oggi 2005; 21 (1): 17-24.

111. Bianchi C, Miccoli R, **Penno G**, Del Prato S. Alterazioni del metabolismo lipoproteico nel diabete mellito tipo 1: aspetti clinici e significato patologico. Il Diabete 2005; 17 (1): 1-15.

112. Miccoli R, **Penno G**, Bonadonna R, Del Prato S. La fenotipizzazione del paziente con diabete tipo 2. Il Diabete 2005; 17 (1): 19-27.

113. **Penno G**, Pucci L, Miccoli R. Spot. Scenari in Medicina Cardiovascolare 2005; 2 (4), pp 24- 27.

114. Roberto M, Pucci L, Bianchi C, **Penno G**. Colesterolo HDL: un nuovo obiettivo della prevenzione cardiovascolare. Scenari in Medicina Cardiovascolare 2005; 2 (6), pp 4-7.

115. Pugliese G, De Cosmo S, Gruden G, Morano S, **Penno G**, Pugliese F, Zerbini G, Gesualdo L, Solini A, Velussi M. Linee guida per lo screening, il monitoraggio, la prevenzione e il trattamento della nefropatia diabetica. Il Diabete 2006; 18 (1): 30-52.

116. **Penno G**, Ghiadoni L, Pucci L, Pantinga Y, Lucchesi D, Triscornia S, Russo E, Giannarelli R, Bernardini M, Bianchi C, Miccoli R, Taddei S, Salvetti A, Del Prato S. Sindrome metabolica e

alterazioni vascolari in soggetti normotesi ad elevato rischio di diabete. XVI Congresso Nazionale Associazione Medici Diabetologi (AMD), Sorrento, 21-24 novembre 2007; Atti; 2007; pp 49-52.

117. Bianchi C, **Penno G**, Agostini A, Giovannitti G, Caricato F, Daniele G, Del Prato S, Miccoli R. Sindrome metabolica e alterazioni vascolari in soggetti normotesi ad elevato rischio di diabete. XVI Congresso Nazionale Associazione Medici Diabetologi (AMD), Sorrento, 21-24 novembre 2007; Atti; 2007; pp 581-584.

118. **Penno G**, Pucci L, Lucchesi D, Bianchi C, Miccoli R. I biomarcatori nella prevenzione cardiovascolare: considerazioni pratiche. Scenari in Medicina Cardiovascolare 2007; 4 (10), pp 8-17.

119. **Penno G**, Pucci L, Lucchesi D, Bianchi C, Miccoli R. La terapia antiaggregante nella prevenzione cardiovascolare: tra vecchi e nuovi farmaci. Scenari in Medicina Cardiovascolare 2007; 4 (11), pp 18-25.

120. **Penno G**, Lucchesi D, Pucci L. La microalbuminuria: cosa si aspetta il clinico. RIMel/IJLaM 2007; 3 (suppl): 130-135.

121. **Penno G**, Pucci L, Miccoli R. La terapia antiaggregante nel paziente diabetico. Pro e Contro. Scenari in Medicina Cardiovascolare 2008; 5 (12), pp 22-23.

122. Miccoli R, Bianchi C, **Penno G**, Del Prato S. Insulin resistance and lipid disorders. Future Lipidol 2008; 3 (6): 651-664.

123. **Penno G**, Pucci L, Lucchesi D, Miccoli R. L'ipertensione nell'anziano: esplorando la letteratura più recente. Scenari in Medicina Cardiovascolare 2008; 5 (13), pp 24-28.

124. **Penno G**, Lucchesi D, Pucci L, Miccoli R. La prevenzione cardiovascolare del paziente diabetico: statine ed altro. Il basso HDL: statine ad alta potenza o altro? Pro e Contro. Scenari in Medicina Cardiovascolare 2010; 7 (15), pp 22-23.

125. **Penno G**, Pucci L, Del Prato S. Il ruolo di zofenopril in Diabetologia. In: Progetto SMILE. Primula Multimedia Editore, 2010, pp 1-9.

126. Pucci L, Lucchesi D, **Penno G**. Integrazione di albuminuria e filtrato glomerulare (GFR) nella stadiazione della nefropatia diabetica. MeDia 2010; 10: 35-38.

127. **Penno G**. Insulina, ipertensione e lipidi. Terapia insulinica nel diabete tipo 2 e complicanze cardio-vascolari. Corso di Alta Formazione SID. Pisa, 14-15 gennaio 2011. Syllabus 2011; pp 65-68.

128. Miccoli R, Bianchi C, **Penno G**, Del Prato S. L'esperienza regionale Toscana nella prevenzione del diabete tipo 2: il programma CArPeDIAB. In: La Prevenzione del Diabete Mellito Tipo 2. Idelson-Gnocchi Editore, 2011; pp 111-115.

129. De Cosmo S, Palena A, Pacilli A, **Penno G**, Lucchesi D, Russo E. Prevenzione dell'insorgenza e della progressione della nefropatia diabetica: controllo glicemico o controllo pressorio? Opinioni a Confronto. Il Diabete 2011; 23 (2): 115-130.

H – Books and book chapters

1. **Penno G**, Giampietro O, Navalesi R. Il rene e l'ipertensione nel diabete mellito. New Trends on ACE-Inhibitors. Vol VII. 1992, pp 1-311; n. 1284 references.

2. **Penno G,** Bandinelli S. Diabete, ipertensione e rischio cardiovascolare. S Del Prato Ed. Editrice Kurtis 2000, pp 1-236; n. 1275 references.

3. **Penno G**, Bandinelli S, Del Prato S. La microalbuminuria nel diabete mellito. In: G Penno, S Bandinelli e S Del Prato Eds. Primula Multimedia Editrice, 2001; 1-112; n. 396 references.

4. **Penno G**, Bandinelli S, Del Prato S. Microalbuminuria, rischio cardiovascolare e disfunzione endoteliale. In: R Pedrinelli Ed. Microalbuminuria: eventi cardiovascolari e nefropatia ipertensiva. Primula Multimedia Editrice, 2002; 42-54.

5. **M**iccoli R, Pucci L, **Penno G**, Del Prato S. Ipercolesterolemia. In: L'endotelio: fisiopatologia e valore clinico. A Salvetti e S Taddei Eds. Monografie di Cardiologia, Arti Grafiche Color Black Editore, 2002; pp 88-95.

6. **Penno G**, Pucci L, Miccoli R, Del Prato S. Terapia ipolipemizzante e disfunzione endoteliale. In: L'endotelio: fisiopatologia e valore clinico. A Salvetti e S Taddei Eds. Monografie di Cardiologia, Arti Grafiche Color Black Editore, 2002; pp 180-189.

7. Del Prato S, Benzi L, **Penno G**, Miccoli R. Postprandial hyperglycemia: present treatment and its importance in the future. In: I Raz, JS Skyler, E Shafrir, Eds. Diabetes – From Research to Diagnosis and Treatment. Martin Dunitz Editor, London and New York, 2003, chapter 17, pp 279-296.

8. Bianchi C, **Penno G**, Del Prato S. Iperglicemia e rischio cardiovascolare. In: S Del Prato ed. Diabete e rischio cardiovascolare. Primula Multimedia Editore, 2006: pp 45-68.

9. Pucci L, Lucchesi D, Fotino C, **Penno G**. Ipertensione arteriosa e rischio cardiovascolare. In: S Del Prato ed. Diabete e Rischio cardiovascolare. Primula Multimedia Editore, 2006: pp 68- 88.

10. **Penno G**, Pucci L. Tiazolidinedioni e nefropatia: studi nell'uomo. In: P Fioretto Ed. Nefropatia diabetica e tiazolidinedioni. Controllo glicemico e oltre. Accademia Nazionale di Medicina. Forum Service Editore 2008; pp 63-72.

11. Del Prato S, Miccoli R, **Penno G**. PPDAT Programma di Prevenzione del Diabete Mellito nella popolazione Adulta della Toscana. Primula Multimedia Editore; 2006, pp 1-128.

12. Del Prato S, Pulizzi N, Lupi R, **Penno G**. Miccoli R. Type 2 diabetes: insulin resistance vs. beta-cell defect. In: Serrano Rios S, Gutierrez Fuentes, Eds. Type 2 Diabetes Mellitus. Elsevier 2010; Chapter 8, pp 131-149.

13. **Penno G**, Bianchi C. La clinica della sindrome metabolica. L'obesità. In: Tiengo A, Del Prato S, Avogaro A, Eds. La Sindrome Metabolica. Mediserve Editoria & Formazione, Milano – Napoli, 2011; pp 71-76.

14. Miccoli R, Daniele G, **Penno G**. La clinica della sindrome metabolica. La dislipidemia. In: Tiengo A, Del Prato S, Avogaro A, Eds. La Sindrome Metabolica. Mediserve Editoria & Formazione, Milano – Napoli, 2011; pp 83-89.

15. **Penno G,** Crisci I. La clinica della syndrome metabolica. Disturbi cognitivi. In: Tiengo A, Del Prato S, Avogaro A, Eds. La Sindrome Metabolica. Mediserve Editoria & Formazione, Milano – Napoli, 2011; pp 127-133.

16. Bianchi C, Daniele G, Miccoli R, **Penno G**. Coordinatore di distretto: S Del Prato. Malattie del metabolismo. Iperuricemia e Gotta; Diabete Mellito, Ipoglicemia, Alterazioni Ereditarie del Metabolismo dei Carboidrati, Dislipidemie, Obesità. In: Manuale Medico di Diagnostica e Terapia ROVERSI. XI Edizione. Merqurio Editore, 2011, pp 639-692.

17. Pugliese G, **Penno G**, Solini A. Nefropatia diabetica e dialisi. In: G Bruno Ed. Il diabete in Italia. Edizioni Minerva Medica, Torino, 2012; pp 103-112.

Pisa, November 16, 2018

SIGNATURE
Giuseppe Penno

